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Xin Tong 
REGULATION OF ENDOPLASMIC RETICULUM CALCIUM HOMEOSTASIS IN 
PANCREATIC β CELLS  
Diabetes mellitus is a group of metabolic diseases characterized by disordered 
insulin secretion from the pancreatic β cell and chronic hyperglycemia. In order to 
maintain adequate levels of insulin secretion, the β cell relies on a highly developed and 
active endoplasmic reticulum (ER). Calcium localized in this compartment serves as a 
cofactor for key proteins and enzymes involved in insulin production and maturation and 
is critical for ER health and function. The ER Ca2+ pool is maintained largely through 
activity of the sarco-endoplasmic reticulum Ca2+ ATPase 2 (SERCA2) pump, which 
pumps two Ca2+ ions into the ER during each catalytic cycle. The goal of our research is 
to understand the molecular mechanisms through which SERCA2 maintains β cell 
function and whole body glucose metabolism. 
Our previous work has revealed marked dysregulation of β cell SERCA2 
expression and activity under diabetic conditions. Using a mixture of pro-inflammatory 
cytokines to model the diabetic milieu, we found that SERCA2 activity and protein 
stability were decreased through nitric oxide and AMP-activated protein kinase (AMPK)-
mediated signaling pathways. Moreover, SERCA2 expression, intracellular Ca2+ storage, 
and β cell death under diabetic conditions were rescued by pharmacologic or genetic 
inhibition of AMPK. These findings provided novel insight into pathways leading to 
altered β cell Ca2+ homeostasis and reduced β cell survival in diabetes.  
To next define the role of SERCA2 in the regulation of whole body glucose 
homeostasis, SERCA2 heterozygous mice (S2HET) were challenged with high fat diet 
(HFD). Compare to wild-type controls, S2HET mice had lower serum insulin and 
significantly reduced glucose tolerance with similar adiposity and systemic and tissue-
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specific insulin sensitivity, suggesting an impairment in insulin secretion rather than 
insulin action. Consistent with this, S2HET mice exhibited reduced β cell mass, 
decreased β cell proliferation, increased ER stress, and impaired insulin production and 
processing. Furthermore, S2HET islets displayed impaired cytosolic Ca2+ oscillations 
and reduced glucose-stimulated insulin secretion, while a small molecule SERCA2 
activator was able to rescue these defects. In aggregate, these data suggest a critical 
role for SERCA2 and the maintenance of ER Ca2+ stores in the β cell compensatory 
response to diet induced obesity. 
 
                                                                         Carmella Evans-Molina, MD, PhD, Chair 
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CHAPTER ONE 
Introduction 
1.1 Diabetes Mellitus 
Diabetes mellitus (DM) is a group of metabolic diseases characterized by 
chronically elevated blood glucose that typically results from either a complete or relative 
lack of the anabolic hormone insulin (1). In certain types of diabetes, the response to 
insulin may also be blunted, a condition known as insulin resistance. Diabetes is a 
widespread disease currently affecting more than 415 million individuals worldwide, and 
this number is estimated to reach 642 million by 2040. Even more striking is the similarly 
drastic number of individuals (318 million) with pre-diabetes or impaired glucose 
tolerance. Importantly, various studies have estimated that 70%-90% of this group will 
develop frank diabetes later in their lives (2). The long-term effects of diabetes mellitus 
include a variety of microvascular and macrovascular complications including 
cardiovascular disease, retinopathy, neuropathy, and nephropathy (3). DM is also a 
major cause of mortality.  Nearly 1.5 million people die annually as a result of the 
disease, and diabetes is also a significant contributor to death from cardiovascular 
causes (4).  
Individuals with DM must carefully manage their blood glucose levels to reduce 
the risk of complications through rigorous life style interventions (5), medications, and in 
certain cases weight reduction surgery (6). While there is currently no cure for DM, 
fundamental basic, translational, and clinical research is critical in providing experimental 
and intellectual insight into both the pathophysiology of this disorder and novel 
prevention or treatment approaches. 
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1.1.1 Different forms of diabetes 
The diagnosis of diabetes has historically been made on the basis of fasting 
blood glucose levels higher than 7 mM (126 mg/dL) or a blood glucose level higher than 
11.1 mM (200 mg/dl) 2 hours (h) after a 75 gram oral glucose tolerance test (7). In 2009, 
a glycated haemoglobin (HbA1C) of 6.5% or higher was also added to the diagnostic 
criteria (8). There are 3 main types of diabetes: Type 1 diabetes (T1D), Type 2 diabetes 
(T2D), and gestational diabetes mellitus (GDM). 
Type 1 diabetes comprises around 5% of all diabetes cases, and is generally 
thought to arise from autoimmune-mediated destruction of pancreatic β cells.  The main 
cause of T1D is infiltration of immune cells into the islet, leading to inflammation, and β 
cell death and dysfunction (9). Thus, the existence of a single or combined circulating 
autoantibodies against β cell antigens is commonly observed in T1D, and this often 
serves as the distinguishing feature between T1D and T2D (10).  T1D was previously 
considered to be a condition of children and adolescents, although this notion of an age 
limitation has changed over the past decade with larger numbers of adults being 
recognized as having T1D. Data suggest that 70-95% of the insulin producing β cells 
have been destroyed at the time of T1D diagnosis (9).  In a recent analysis based on the 
Network for Pancreatic Organ Donors Database (nPOD), single antibody positive non-
diabetic subjects were found to have equivalent β cell mass with antibody negative 
control subjects. It was only when the disease progressed that the majority of β cell loss 
was observed. This suggests that additional research is needed to fully define the 
dynamics of β cell destruction in the preclinical phase of T1D (11).  
T2D accounts for about 90-95% of diabetes cases and is a metabolic disorder 
that is highly associated with obesity. This form of diabetes is characterized by insulin 
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resistance coupled with inadequate insulin secretion from the pancreatic β cells (2). 
During the progression to T2D and in response to insulin resistance and chronic fuel 
surfeit, the β cells undergo an adaptive phase characterized by compensatory 
hyperplasia and insulin hypersecretion in order to meet increasing metabolic demands 
(12). Clinically apparent diabetes develops only in subjects who fail to maintain this 
compensatory response.  In susceptible individuals, this transition is marked by a 
significant loss of β cell mass, function, and identity (13-15).  T2D is also a disease with 
high prevalence of co-morbidities. In a cohort of over 1,389,016 individuals with T2D, 
over 97.5% were found to have at least one comorbid condition, and 88.5% had at least 
two. The most common co-morbid conditions included hypertension, overweight/obesity, 
and hyperlipidemia (16).  
Gestational diabetes mellitus (GDM) is defined as hyperglycemia that is first 
detected at any time during pregnancy. This form of diabetes is seen in about 7% of all 
pregnancies. Women with obesity, glucose intolerance, a first-degree relative with T2D, 
or a history of gestational diabetes are at increased risk of developing GDM (17). GDM 
tends to occur after the 24th week of pregnancy due to increased insulin resistance and 
inadequate β cell compensation.  However, symptoms normally disappear after birth. Yet 
women who have been previously diagnosed with GDM have an increased risk of 
diabetes in subsequent pregnancies. Moreover, 70% of all women with gestational 
diabetes will develop T2D later in their lives (18). Babies born to mothers with 
gestational diabetes also have a higher risk of developing T2D in their teens or early 
adulthood (19).  
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1.1.2 Mechanisms of glucose homeostasis 
Glucose is the main fuel type for most biological processes. This carbohydrate 
provides energy in the form of ATP through metabolism by glycolysis and the citric acid 
or tricarboxylic acid (TCA) cycle. Under most physiological conditions, blood glucose 
levels are controlled by a balance between glucose appearance in the circulation and 
glucose uptake/metabolism. Glucose appearance is mediated by meal-derived sources 
and endogenous glucose production mainly from the liver. Glucose disappearance 
occurs mainly in response to insulin stimulated uptake in peripheral tissues (20). Under 
normal conditions, blood glucose levels oscillate within a very controlled range.  In the 
fasting state, glucose levels are usually below 99 mg/dL, and blood glucose levels are 
kept below 139 mg/dL in the post-meal state (7). Depending on the specific physiological 
cues during post-meal and fasting states, distinctive profiles of hormones are secreted 
from the pancreas, gut, and brain to regulate the uptake and metabolism of glucose in 
peripheral tissues including the liver, muscle, and adipose tissue.  
Several hormones secreted from pancreas, brain and gut including glucagon, 
glucocorticoids and epinephrine work on peripheral tissues to increase blood glucose 
levels through processes including gluconeogenesis and glycogenolysis (20). On the 
contrary, insulin secreted from pancreatic islets is the only hormone that acts to 
decrease blood glucose and promote glucose utilization and/or storage. Specifically, 
insulin binds to the insulin receptor on the surface of a target cell, triggering a series of 
phosphorylation events starting with a tyrosine kinase and insulin responsive substrates 
(IRSs) (21). These IRSs serve as docking proteins that further activate downstream 
signaling pathways, initiating mostly anabolic actions.  These actions include glucose 
transport, glycogen synthesis, lipogenesis, protein synthesis and cellular growth. 
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Meanwhile, insulin signaling also suppresses gluconeogenesis in the liver, protein 
hydrolysis in skeletal muscle and lipolysis in adipose tissue (22). 
1.2. Pancreatic Islets and the β cell under normal conditions 
1.2.1 Pancreatic islet composition and distribution 
Pancreas is an endocrine organ that lies in the upper left part of the abdomen. 
Anatomically, the pancreas is divided into a head, which rests within the concavity of the 
duodenum, a body lying behind the base of the stomach, and a tail, which is near the 
hilum of the spleen. Approximately 3 million cell clusters called pancreatic islets are 
present in the pancreas (23). They are groups of endocrine cells that secrete a multitude 
of hormones including insulin (β cells), glucagon (α cells), somatostatin (δ cells), 
pancreatic polypeptide (PP cells) and ghrelin (ε cells). The composition, size and 
structure of islets shows a wide range of variability at both the individual and species 
level (24). For example, in rodents, a central core of β cells makes up 60–80% of the 
islet, while a layer of α cells (15–20%), δ cells (<10%) and PP cells (<1%) surround the 
core. The composition of human islets, on the other hand, includes a lower percentage 
of β cells (~50%),  α cells (~40%),  δ cells (10%) and few PP cells (25). Human islets 
also have a structure where different cell types tend to be randomly distributed (26). 
Furthermore, pancreas comprise head which is the , studies of different regions of the 
human pancreas have revealed: 1) that the density of islets is similar between the head 
and body regions, but is 2-fold higher in the tail region, 2) no differences exist in glucose-
stimulated insulin secretion patterns in islets isolated from different regions, and 3) 
persons with T2D exhibit a preferential loss of large islets in the head region (27).  
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Figure 1. Ca2+ regulators and the involvement of Ca2+ in β cell homeostasis. 
To meet the continuous needs of finely-tuned insulin secretion, the β cell possesses a 
highly developed ER that plays a central role in protein synthesis, signal transduction, 
and Ca2+ storage. Under normal conditions, the precise regulation of the steep Ca2+ 
gradient between the cytosol and the ER lumen is maintained by the sarco-endoplasmic 
reticulum Ca2+ ATPase (SERCA) pump together with Ryanodine (RyR) and IP3 receptors 
(IP3R).  This Ca2+ gradient is critical for many β cell functions including insulin 
biosynthesis, insulin secretion, and cellular signal transduction. Mainly two aspects 
contribute to the transient elevation of cytosolic Ca2+ concentration that ultimately 
induces insulin secretory granule (SG) exocytosis.  In the first, glucose is transported 
through a glucose transporter (GLUT2). The glucose metabolism leads to an increase in 
the ATP/ADP ratio. This change triggers closure of KATP channels and the subsequent 
opening of voltage gated Ca2+ channels (VOC).  In the second mechanism, incretins, 
which are hormones that released from the gut into the blood stream after ingestion of a 
meal, activate G-protein coupled receptors (GPCR) to induce cAMP elevation which 
activates IP3R/RyR to release Ca2+ from ER. The clearance of excess cytosolic Ca2+ is 
dependent on SERCA, the plasma membrane Ca2+ ATPase (PMCA) and the sodium 
calcium exchanger (NCX).  
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1.2.2 Ca2+ involvement in the function of pancreatic β cell  
Similar to other peptide hormone secreting cells, pancreatic β cells have 
specialized machinery to meet the needs of continuous protein synthesis and secretion. 
At peak rates, it is estimated that β cells are capable of producing up to 1 million 
molecules of proinsulin per minute (28). To meet this high demand of insulin 
biosynthesis, the β cell has a highly developed endoplasmic reticulum (ER) that plays a 
central role in protein synthesis and Ca2+ storage. Ca2+ within the ER and secretory 
granules play a critical role in insulin production, processing, and maturation (29-31). 
Ultimately, insulin-containing secretory granules are released through exocytosis in 
response to physiological cues. This event, termed stimulus-secretion coupling, is 
primarily a Ca2+ dependent event. Because of the central role of Ca2+ in insulin 
biosynthesis and stimulus-secretion coupling, understanding the pathways regulating β 
cell Ca2+ homeostasis under normal and diabetic conditions has been the focus of my 
dissertation work. A schematic graph summarizing key molecular regulators of Ca2+ in 
the β cell is shown in Figure 1 and is discussed in further detail in the following sections. 
a. Mechanisms of insulin biosynthesis  
Mice have two insulin genes located on chromosome 6 and 7, Ins1 and Ins2 (32, 
33) whereas humans have a single insulin gene located on chromosome 11 (34).  Insulin 
mRNA is estimated to occupy ~20% of total mRNA in the β cell under physiological 
conditions (33).   
The insulin genes encode a 110-amino acid precursor known as preproinsulin. 
After translation, preproinsulin is recognized by the rough ER through its signal 
recognition particle (SRP).  The SRP is subsequently cleaved by signal peptidase to 
form proinsulin, which contains 86 amino acids. After folding and formation of three 
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critical disulfide bonds in the ER, proinsulin is transported into the Trans-Golgi network 
(TGN), where it is packaged and sorted into immature secretory granules. Several key 
maturation steps occur within immature granules: 1) the granules become acidified via 
ATP-dependent proton pump activity; 2) proinsulin undergoes proteolytic cleavage by 
calcium-dependent protein convertase 1/3 (PC1/3) and PC2 and carboxypeptidase E 
(CPE), resulting in equal molar amounts of insulin and C-peptide; 3) zinc and Ca2+ 
facilitate the crystallization of insulin. The final products of these steps are the dense-
core granules that enter the constitutive trafficking pathway for secretion (35). In a 
mouse β cell, there are roughly 13,000 insulin granules and each contains approximately 
200,000 insulin molecules (36, 37).   
A number of factors are required to support the high biosynthetic burden of 
insulin production.  Chief among them is a robust ER Ca2+ pool. Under normal conditions, 
Ca2+ is distributed unevenly within the cell. A steep gradient exists between the cytosol, 
where the Ca2+ concentration is estimated to be 50-100 nM, and the ER lumen, where 
the Ca2+ concentration is measured to be 30-300 µM (38-40). The high concentration of 
Ca2+ within the ER lumen serves as a required cofactor for a number of steps involved 
insulin production (41). Most notably, the ER lumen contains several Ca2+ related 
chaperones including calreticulin, heat shock protein 90 kDa β member 1 (HSP90B1 or 
Grp94), binding immunoglobulin protein (BiP) and protein disulfide-isomerase (PDI) that 
facilitate protein and lipid synthesis (42). Furthermore, previous work has shown that the 
ER Ca2+ pool serves as the main source of Ca2+ within the secretory granules where the 
Ca2+-dependent convertase enzymes complete the final steps of insulin protein 
maturation (31).  
Nutrient metabolism, especially that of glucose, is one of the dominant driving 
factors of insulin transcription and translation. The glucose effect on insulin transcription 
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is to enhance the production of insulin mRNA and to increase its stability. Notably, 
compared to mature insulin mRNA, unprocessed intron-containing pre-mRNA has a 
significantly shorter half-life, suggesting that insulin pre-mRNA might serve as a better 
candidate in measuring the acute response to glucose at the transcriptional level (43). 
Meanwhile, the translational regulation of insulin in response to glucose is also very 
rapid, with a 20-fold increase in insulin protein occurring within minutes of glucose 
stimulation (36).  
b. Ca2+ channels and pumps in β cells.   
ER Ca2+ regulators 
Three Ca2+ pumps or channels are located on the ER membrane and maintain 
the dynamic Ca2+ concentration within this organelle.  These include the 
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) pump, ryanodine receptors (RyR) 
and inositol 1,4,5-trisphosphate receptors (IP3R). The SERCA protein is a P-type 
ATPase that serves as the primary regulator of ER Ca2+ homeostasis (discussed in 
detail in Section 1.4). The SERCA pump hydrolyses 1 ATP molecule in order to move 2 
Ca2+ molecules from the cytosol into the ER lumen, thereby actively maintaining the 
steep Ca2+ gradient that exists between the ER and cytosol (44). In contrast, the IP3Rs 
and RyRs are Ca2+ release channels that empty ER Ca2+ in a ligand-gated and passive 
manner. Notably, expression levels and activity of IP3Rs and RyRs have been found to 
be significantly lower than the expression of SERCAs in β cells (45). However, 
interestingly, all isoforms of IP3Rs were found to localize to insulin secretory granule 
membranes, with a 2-fold abundance compared to the ER membrane, suggesting a role 
for IP3R in granule function (46). 
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Plasma Ca2+ transporters 
ER Ca2+ storage is also indirectly maintained by two Ca2+ transporters on the 
plasma membrane: the Na+/Ca2+-exchanger (NCX) and the plasma membrane Ca2+ 
ATPase (PMCA). These transporters actively move Ca2+ against a tremendous 
concentration gradient from the inside to the outside of the cell to maintain relatively low 
cytosolic Ca2+ concentrations. PMCA was found to have at least 6 variants with tissue 
specific functions, while NCX contributes to both Ca2+ outflow and influx and has been 
shown to regulate insulin release (47, 48).  
c. Mechanisms of insulin secretion 
Insulin secretion is mediated by exocytosis of insulin granules in response to a 
variety of secretagogues including glucose, amino acids, free fatty acids (FFA) and 
incretin hormones (49-51). There are mainly 2 routes that will induce the exocytosis of 
insulin granules. The first depends on β cell depolarization-induced Ca2+ mobilization.  
Glucose is the most important stimuli for this canonical pathway of insulin secretion. In 
the post-prandial state, when blood glucose rises, glucose molecules are transported 
into the β cell through the glucose transporter (GLUT2 in rodents or GLUT1 in humans) 
(52).  Glucose is metabolized by glycolysis and the TCA cycle, leading to generation of 
ATP and an increase in the ATP/ADP ratio. This elevation triggers closure of KATP 
channels, resulting in β cell depolarization and Ca2+ influx through opening of voltage-
gated Ca2+ channels (VOC) on the plasma membrane (53). Increased cytosolic Ca2+ will 
induce immediate fusion of insulin granules with the plasma membrane to release insulin. 
Also, treatments that increase cytosolic Ca2+, such as the application of thapsigargin to 
inhibit SERCA activity, can acutely induce insulin secretion (29, 54).   
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Insulin secretion can be amplified by the second route which involves cyclic 
adenosine monophosphate (cAMP) upregulation, which activates Ca2+ release channels 
located on the ER. This route of release is the main mechanism by which the incretin 
hormones, glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide, induce 
insulin secretion (GIP) (51). The binding to specific G-protein coupled receptors (GPCR) 
located on the β cell plasma membrane, activates adenylate cyclase causing an 
increase in cytosolic cAMP, which in turn activates protein kinase A (PKA). PKA then 
phosphorylates RyRs and IP3Rs to increase their activity. In the meantime, cAMP can 
also directly bind to Epac2 which is a guanine nucleotide exchange factor for the Ras-
like small GTPase Rap. Rap subsequently acts on phospholipase C ε (PLC-ε) to 
generate IP3 which induces Ca2+ efflux from the ER and results in insulin granule 
exocytosis (55, 56). Increased cytosolic Ca2+ then potentiates a sustained release of 
Ca2+ from the ER, which will further facilitate insulin secretion (57). The insulinotropic 
effects of incretins were further confirmed by inactivation of both GLP-1 and GIP 
receptors in β cells. This inactivation of the incretin receptors resulted in defect in 
stimulated insulin secretion (58, 59). Despite having similar molecular mechanisms, 
GLP-1 and GIP have distinct roles in T2D. Specifically, GIP action is lost in β cells during 
T2D due to a desensitized GIP receptor (GIPR) or decreased expression of the GIPR 
whereas GLP-1 is still fully functional. However, due to low circulating GLP-1 levels in 
T2D, potentiated insulin secretion by oral glucose administration is blunted (60).  
Over 50 years ago, it was discovered that insulin secretion is characterized by a 
biphasic pattern (61-63). Mature secretory granules can be divided into a readily 
releasable pool (RRP) and a reserve pool, depending on their proximity to the plasma 
membrane. The RRP is proximal to the plasma membrane and comprises about 5% of 
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insulin granules, while the vast majority (~95%) of granules are found in the reserve pool 
located deeper in the cytosol (30).  
Ca2+ has long been considered the direct driving factor of insulin granule 
exocytosis.  Thus, insulin secretion in β cells and a Ca2+ wave almost always parallel 
with the amount of insulin secreted with the exception of ob/ob islets under certain 
conditions (64). Following glucose or incretin hormone stimulation, acute elevations of 
cytosolic Ca2+ drive the exocytotic fusion of secretory granules in the RRP with the 
plasma membrane. This forms the typical 1st phase of insulin secretion. Following the 
acute phase, a sustained release of ER Ca2+ through Ca2+ induced Ca2+ release (CICR) 
occurs and mediates the formation of Ca2+ oscillations. These regulated oscillations 
drive the movement of reserve pool granules towards the plasma membrane, initiating 
pulsatile insulin secretion. This slower yet relatively sustained event forms the 2nd phase 
of insulin secretion (30). Indeed, pulsatile insulin secretion has been observed under 
basal conditions or during the 2nd phase with a parallel cytosolic Ca2+ oscillation (65-68).  
Several factors regulate Ca2+ oscillation and pulsatile insulin secretion. First, ER 
Ca2+ has been shown to play a critical role in CICR and in the regulation of Ca2+ 
oscillations (68), as inhibition of RyR/IP3R and ER Ca2+ depletion attenuate both 
processes (69, 70). Metabolic signals are also involved and their influence has been 
proposed in the glycolytic oscillation model (71). In support of this model, cAMP levels 
and ATP production from glycolysis have been shown to have a similar oscillatory 
pattern. This is mainly based on oscillatory changes in the activity of the glycolytic 
enzyme phosphofructokinase (PFK) (72, 73). In a recent series of studies, a refined dual 
oscillation model was proposed that has taken into consideration both metabolic and 
Ca2+ feedback effects on PFK activity (74, 75). This is a more comprehensive model that 
mathematically represents all of the observations above, as well as the distinct types of 
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oscillatory patterns.  In this regard, there are two types of Ca2+ oscillations observed in β 
cells: slow oscillations (with frequency of ~0.2-0.5/min) and fast oscillations (2–3/min). It 
is believed that fast oscillations are more regulated by changes in membrane potential, 
while glycolytic oscillations are more greatly influenced  by slow Ca2+ oscillations (76).  
Finally, a key component of healthy oscillations depends upon efficient 
mechanisms to clear the elevations in cytosolic Ca2+ (77). Excess Ca2+ can be either 
extruded to the extracellular space by NCX or PMCA or taken up into the ER lumen by 
SERCA. A number of studies suggest that the ER serves as the most critical buffering 
system in these processes and that SERCA activity is responsible for the majority of 
Ca2+ clearance from the cytosol.  Specifically, mathematical modelling suggests that 
SERCA activity is responsible for clearing upwards of 60% of cytosolic Ca2+ following 
glucose stimulation (78).  
As individuals progress from normal glucose tolerance to impaired glucose 
tolerance, changes in the β cell secretory pattern occur (79). Both impaired pulsatility (80) 
and abnormal biphasic secretion patterns (81) are found in T2D. Specifically, during the 
early stages of glucose intolerance, 1st phase insulin secretion is decreased (82), while 
later stages of glucose intolerance result in lower 2nd phase insulin secretion (82-86). 
Persons with T2D also fail to respond adequately with regular oscillatory insulin 
secretion in response to glucose excursions (87). A dysregulated oscillatory pattern is 
also found in rodent diabetes models (88, 89). Taken together, these observations 
suggest a critical role of cellular Ca2+ homeostasis in the regulation of Ca2+ oscillations 
and insulin secretion (90)  
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d. Other factors regulating insulin secretion 
Another important factor regulating insulin secretion is cell-cell contact within the 
islet and between individual β cells. For example, dispersion of islets into a single cell 
suspension dramatically reduces glucose stimulated insulin secretion (91-93). A recent 
study using a mouse knock-out model of connexin 36, a gap junction protein, 
demonstrated a significant impairment in both 1st and 2nd phase insulin secretion.  
Connexin 36 knock-out was sufficient to cause whole body glucose intolerance, thus 
indicating the importance of cell attachment in the dynamics of insulin secretion and 
coordinated pulsatility of individual islets (94). This inter-cell communication likely 
involves Ca2+ since dispersed β cells are more depolarized at a resting state, yet failed 
to mount additional Ca2+ responses when exposed to glucose (91). These gap junctions 
within intact islets also allow for the synchronous pattern of cytosolic Ca2+ waves that 
support healthy oscillation patterns (67).  
e. The role of Zinc in insulin production and secretion.   
In addition to Ca2+ ions, zinc (Zn2+) also plays an important role in insulin 
granulogenesis. Early on, it had been suggested that Zn2+ deficiency was linked to both 
T1D and T2D in terms of impairments in insulin production (95). However, it wasn’t until 
2004 that Fabrice Chimienti (96) and colleagues first identified and cloned the Zn2+ 
transporter 8 gene (ZnT-8) from β cells. It was found that the ZnT-8 protein co-localizes 
with insulin in the secretory granule, which suggests a critical role for Zn2+ in insulin 
maturation and storage (96). Indeed, in vivo studies using ZnT-8 whole body knock out 
or β cell specific knockout mice demonstrated that although whole body glucose 
homeostasis was not dramatically compromised, there were consistent β cell insulin 
packaging defects in ZnT-8 deficient conditions (97, 98).  This finding was further 
15 
confirmed by an epidemiological study analyzing the interaction of plasma Zn2+ and a 
loss-of-function single nucleotide polymorphism (SNP) of ZnT-8 gene (SLC30A8 
rs13266634) in persons with T2D. The results indicated that this SNP was associate with 
lower plasma Zn2+ levels, which increased the odds ratio for T2D and impaired glucose 
tolerance (IGT) (99). Interestingly, a newly characterized Zn2+  transporter (Zn2+  influx 
transporters or ZIP) was recently found to facilitate insulin exocytosis, thus increasing 
glucose-stimulated insulin secretion without altering insulin production or β cell identity 
(100).    
In summary, insulin biosynthesis and secretion are regulated at multiple levels 
and each step is critical to ensure optimal glucose stimulated insulin secretion (101, 102). 
Many of these steps involve Ca2+ dependent mechanisms, which represent potential 
therapeutic targets. Therefore, a more complete understanding of how Ca2+ homeostasis 
is coordinated and maintained in β cells is necessary for future therapeutic strategies to 
prevent the development of frank T2D  
1.3 Natural History of T2D and Deterioration of β Cell Mass and Function  
1.3.1 Insulin resistance and compensation in β cells 
Clinical studies have provided insight into the natural history of T2D.  In a 
longitudinal study, researchers measured plasma glucose levels 2 h after a glucose 
tolerance tests in Pima Indians, a group known to have a high genetic risk of T2D.  
Results indicated that there were two distinct stages in most individuals during their 
progression to T2D. Blood glucose levels usually became slightly elevated 20-30 years 
before diabetes diagnosis. Then, an exponential stage of dsyglycemia appeared.  During 
this phase, blood glucose levels quickly increased over 4-5 years prior to clinical 
16 
diagnosis. This observation indicates a key transition stage with a rapid glucose rise that 
differentiates individuals who develop frank diabetes from those who do not (103).  
Increasing insulin resistance in peripheral tissues and β cell failure have both 
been shown to contribute to progression of T2D (104). Insulin resistance is observed in 
the majority of people with T2D, especially those who are overweight or obese (105). 
Insulin resistance is defined as the inability of insulin to produce its usual biological 
effects at physiological concentrations.  This defect leads to impaired inhibition of 
hepatic glucose output, glucose uptake into skeletal muscle, and suppression of lipolysis 
in adipose tissue (106). Whereas it is difficult to find the true initiating factor in the 
development of insulin resistance in a pathological setting, several factors including 
chronic inflammation, lipid accumulation, and changes in gut microbiota have been 
found to contribute to insulin resistance (107). Notably, both high fat diet (HFD)-fed 
animals and individuals with T2D exhibit an accumulation of diacylglycerol (DAG) in 
skeletal muscle and liver. The DAG leads to defects in insulin-stimulated glucose 
transport activity in skeletal muscle and induces steatotosis in the liver, leading to 
inhibition of hepatic glucose production and stimulation of glycogen synthesis (108, 109).  
Mechanistically, three main aspects contribute to lipid-induced insulin resistance: 
ectopic lipid accumulation, the development of ‘‘endoplasmic reticulum stress’’ and the 
contribution of systemic inflammation (110). In regard to systemic inflammation, 
adipokines secreted by white adipose tissue (WAT) were found to be highly involved, 
especially in the visceral fat depots. Unlike subcutaneous fat depots, visceral fat has 
higher adipose tissue macrophage (ATMs) accumulation (111). In the obese state, 
adipocytes together with pro-inflammatory ATMs preferentially secrete pro-inflammatory 
factors such as tumor necrosis factor α (TNF-𝛼𝛼), interleukin-6 (IL-6). These factors 
directly or indirectly activate c-Jun N-terminal kinases (JNK) and IκB kinase (IKKβ) 
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signaling pathways that phosphorylate the inhibitory serine residues of IRS-1 (Serine307 
in rat and Serine312 in human) to blunt insulin-mediated signal transduction (112-114). 
These factors  can also work through suppressor of cytokine signaling (SOCS) proteins, 
which directly bind to the insulin receptor to inhibit phosphorylation at activating tyrosine 
residues (115). In contrast to WAT, brown adipose tissue (BAT) has been found to be 
protective and capable of increasing the basal metabolic rate and improving insulin 
sensitivity. Several studies in both mouse and humans suggest BAT may be a promising 
anti-diabetic tissue (116, 117).  
Whereas increased peripheral insulin resistance is a key factor pathogenic state 
contributing to the development of T2D, insufficient insulin secretion has been suggested 
as the key determining factor leading to the development of frank diabetes (118, 119). 
During a stage known as compensation, the β cells are continually challenged to match 
insulin resistance with increased insulin output by expansion in both mass and secretory 
capacity (120). For example, with short-term glucose infusions in rats, β cell mass 
doubled within 6 days, leading to augmented insulin production (13). Another commonly 
used animal model for this compensation stage is HFD fed mice. After 16-20 weeks of 
HFD with 42-60% calories from fat, β cell mass was found expanded to over 2-fold in 
C57BL6 mice (121). Insulin output was also increasing progressively by time during HFD 
while maintaining euglycemia (122). Interestingly, in this relatively short period of 
challenge, the expression of key β cell genes remained normal and the function of 
individual β cell remained almost unchanged (123). It is the failure to maintain the 
compensation that leads to development of diabetes, and this will be discussed in detail 
in section 1.3.2. 
In adults, pancreatic β cell mass is controlled by several mechanisms, including β 
cell replication, neogenesis, hypertrophy, and survival (124). β cell proliferation has been 
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relatively well studied in rodent models. Multiple stimuli from other organs coordinate to 
trigger initiation of the cell cycle leading to hyperplasia of β cells. These factors include 
glucose, insulin, incretins, adiponectin, cytokines (125) and hepatocyte growth factor 
(126, 127). These factors activate a large number of cellular signaling pathways involved 
in β cell proliferation and the list continues to grow (128, 129). For example, glucokinase 
(Gck) and IRS-2 was found to be critical in this compensatory response, as mice with β 
cell–specific haploinsufficiency of Gck or knock out of IRS-2 lose the capacity to expand 
their β cell pool in response to obesity (121, 130). Mechanistically, target of rapamycin 
(mTOR) is also a classic signaling pathway that contributes to up-regulation of β cell 
proliferation (131, 132). Incretins, including GLP-1 and GIP, facilitate β cell proliferation 
by up-regulating the anti-apoptotic-cell lymphoma 2 (BCL-2) gene through cAMP 
response element binding protein (CREB) signaling (133). cyclin D2 is also suggested to 
be key in controlling β cell proliferation upon HFD challenge (134, 135). On the other 
hand, adult human β cells do not appear to replicate in response to the same growth 
factors and nutrients that induce rodent β cell replication (128). Whereas age is certainly 
a critical factor determining the division potential of β cells, proliferation is still quite rare 
in human β cells. Notably, only 2-3% of human β cells were found to proliferate even 
during infancy. This number further dropped to 0.2% in adult β cells (136). Thus, 
targeting proliferation in adult humans under physiological conditions is challenging. 
Nevertheless, human β cells can be stimulated to replicate when cyclins and cyclin-
dependent kinase (CDKs) are overexpressed (137). A recent proteomic study in human 
pancreatic cells revealed the critical role of cdk6 and cyclin D1(138). These discoveries 
indicate that a better understanding of human β cell proliferation is essential (129).  
In addition to an increase in β cell proliferation and hypertrophy, hypersecretion 
of insulin from individual β cells also appears to contribute to this compensatory 
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response. Hypersecretion of insulin occurs via several mechanisms. First, secretory 
granule biogenesis is higher during compensation (139). Second, due to larger 
amplitude action potentials that increase Ca2+ signals, glucose-induced insulin secretion 
during this compensation stage is also increased (140). Third, it has been observed that 
a group of genes involved in glucose phosphorylation that are normally suppressed, 
including hexokinase 1 and glucose-6-phosphatase, were markedly upregulated during 
obesity, leading to higher insulin secretion at similar glucose levels (13, 141). 
1.3.2 Factors contributing to β cell dysfunction and loss during T2D progression 
Unfortunately, the ability of β cells to maintain this compensatory state eventually 
fails in certain groups of individuals and it has been estimated that 30-50% of 
prediabetes or with IGT will develop diabetes within 5 years (142). As the blood glucose 
levels increase, persons with impaired fasting glucose or glucose intolerance often 
progress to a state of declining β cell mass and function (13, 143, 144). A 2004 study 
analyzing a limited number of cadaveric donor pancreata  from both non-diabetic 
individuals and persons with frank T2D demonstrated a nearly 50% lower islet mass in 
those with diabetes. T2D islets were also noted to be smaller on average and contain a 
higher percentage of glucagon producing cells (145). Indeed, this decreased β cell mass 
was confirmed in several other studies (146-148).  
These failures in compensation can be attributed to both genetic and 
environmental factors. With regard to genetics, T2D is primarily considered to be 
polygenic in nature (149, 150). However, genome wide association studies (GWAS) 
have begun to identify T2D susceptibility loci. In two GWAS performed in 2010 and 2013, 
40 loci that have strong association with higher incidence of T2D were identified. These 
loci can be categorized into genes that regulate insulin resistance/action (e.g. PPARG, 
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FTO and KLF14), insulin processing (e.g. MTNR1B, GCK) and insulin secretion (e.g. 
KCNQ1, BCL11A, HNF1A, SLC30A8 and CAMK1D, TCF7L2, HHEX/IDE, CDKAL1, 
CDKN2A/2B). Also, evidence of enrichment for genes involved in cell cycle regulation 
was found to be associated with T2D (151, 152).  Notably, but not surprisingly, similar 
studies performed in women with GDM, which shares overlap with T2D, showed that 
T2D and GDM share some susceptibility loci like KCNJ11, GCK, and HNF4a (153). In 
aggregate, though, the majority of GWAS studies have highlighted a prominent role for 
loci that impact the β cell.  
In addition to these genetic factors, extrinsic factors may also have important 
detrimental effects that contribute to the decompensation of β cells. These include 
hyperglycemia, glucolipotoxicity (GLT), pro-inflammatory cytokine stress, alterations in 
the redox state, accumulation of unfolded proteins in the ER, and disturbances in Ca2+ 
homeostasis (154). In the following section, the main factors involved in declining β cell 
function and mass in T2D will be discussed. 
a. Glucotoxicity and lipotoxicity 
The first and probably foremost insult during the development of T2D includes a 
chronic elevation of blood glucose. Multiple studies indicate that acute or prolonged 
hyperglycemia impairs β cell function.  In non-diabetic animals, short term glucose 
infusions decreased the glucose sensitivity of β cell to secrete insulin, without inducing 
overt oxidative stress (155). However, prolonged culturing of isolated islets from 
cadaveric organ donors in 28 mM glucose significantly decreased insulin content, rates 
of glucose oxidation, proinsulin biosynthesis, and total protein biosynthesis, indicating 
stressed islets (156). Furthermore, hyperglycemia decreased the expression of key β 
cell genes including pancreas/duodenum homeobox protein 1 (Pdx-1), 
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musculoaponeurotic fibrosarcoma oncogene homolog A (MafA) and insulin (Ins1 and 
Ins2) (157).  This elevated glucose level also induced alterations in expression of genes 
involved in glucose metabolism, causing desensitization to glucose stimuli (158). 
Hyperglycemia can induce expression of a series of stress response genes, including 
those involved in oxidative stress, ER stress, hypoxia (159) and protein glycation (160). 
The induction of ER stress and oxidative stress signals were directly detected after in 
vivo glucose perfusion performed in rats to raise blood glucose levels to 20-22 mM (161). 
In addition, glucotoxicity has been shown to transcriptionally activate thioredoxin-
interacting protein (TXNIP) via CREB, which induces β cell apoptosis (162). Interestingly, 
hyperglycemia-induced TXNIP up-regulation also activates IL-1β expression in cultured 
human adipose tissue (163), thus opening up the question of whether this mechanism 
exists in β cells under hyperglycemic conditions. In support of this idea, TXNIP 
overexpression in β cells resulted in increased inflammasome activation and IL-1β 
expression (164). 
Hyperlipidemia, elevated levels of non-esterified fatty acids (NEFA), has also 
been associated with an increased risk of prediabetes and diabetes (165, 166). 
Decreased NEFA, on the other hand, improved GSIS and decreased insulin resistance 
in peripheral tissues (167). However, lipids may serve as a double-edged sword with 
regard to their effects on β cell function and survival, as the dose and specific types of 
NEFA or triglyceride dictate their net effects. Short term perfusion of NEFA was found to 
potentiate GSIS (168). However, this hypersecretion phenomenon slowly exerted 
detrimental effects on β cell secretory machinery and survival, potentially through nitric 
oxide-dependent stress (169, 170), pro-inflammatory signal activation (171, 172), 
alterations in the microRNA (miRNA) profiles (173) and ER stress induction (174). These 
alterations directly or indirectly delayed the processing by PC1/3 and PC2, increased the 
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proinsulin to insulin ratio and decreased overall response of glucose stimulated insulin 
secretion (175, 176). Different types and metabolites of NEFA showed varied effects on 
β cell function and whole body glucose homeostasis. For example, poly-unsaturated 
fatty acids resulted in a reduction in insulin secretion, while saturated fatty acids induced 
insulin resistance (177).  
GLT is another commonly used model that mimics the combined toxic conditions 
of hyperglycemia and hyperlipidemia observed during obesity and T2D. In most cases, 
elevated levels of lipids only exert detrimental effects when glucose levels are also high 
(178). This combined treatment with lipids and glucose was found to have more robust 
deleterious effects on β cell function and survival when compared to either alone (179). 
However, it should also be noted that GLT induced a period of adaptation/compensation 
when β cell metabolism adjusted to utilizing lipid, thus augmenting insulin secretion. 
Genetic predisposition likely determines whether GLT results in β cell compensation or 
apoptosis (180). Indeed, different strains of mice demonstrate various compensatory 
responses under HFD-induced obesity (181).  
b. Pro-inflammatory cytokines 
Elevations in pro-inflammatory cytokines including IL-1β, tumor necrosis factor α 
(TNF-α) and interferon γ (IFN-γ) are commonly seen during the development of T1D.  
Interestingly, in a recent epidemiological study of persons with prediabetes or T2D, it 
was found that the inflammatory profile changed in parallel with disease progression, 
suggesting that pro-inflammatory cytokines also play an important role in the 
development of T2D (182). The majority of these pro-inflammatory cytokines are 
secreted from immune cells such as macrophages and activated T cells that reside in or 
invade islets (183). This idea was supported by a recent study utilizing cultured islets 
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overexpressing human islet amyloid polypeptide (IAPP), which aggregates to form 
amyloid fibrils in people with T2D and acts as a potent stimulator of IL-1β secretion from 
bone marrow–derived macrophages. In this study, upregulation of IL-1β was only found 
in resident macrophages, but not in other cell types (184). Despite inconsistent results 
from different groups, it has been suggested that β cells might also secrete small amount 
of cytokines in the context of diabetic stressors including GLT (185, 186). Interestingly, 
FFAs were found to increase the expression of IL-1 receptor 1 through toll like receptor-
mediated signaling pathways. This pathway acts as a signal amplifier for pro-
inflammatory stimuli and may serve as a mutual mechanistic connection between T1D 
and T2D (185, 187, 188).  
Cytokines contribute to β cell death through a variety of pathways.  For example, 
cytokines also  induce expression of several miRNAs including miR21, miR34a and 
miR146a, which have been shown to contribute to pro-death pathways (189). The 
expression of p53 upregulated modulator of apoptosis (PUMA) was also up-regulated in 
response to cytokine treatment. These changes impaired protein chaperone profiles and 
changed the ratio of Bcl2-associated X protein (BAX) to Bcl-2, to induce apoptosis (190).  
Cytokines also have prominent effects to activate of ER stress and apoptosis.  
These actions are thought to primarily be nitric oxide (NO)-dependent (191) and involve 
activation  of NF-kB signaling pathways (192). For example, IL-1β strongly induces NO 
production through inducible nitric oxide synthase (iNOS), while islets isolated from 
iNOS null mice showed decreased apoptosis when exposed to IL-1β (193).  NO was 
found to exert its detrimental apoptotic effects through activation of ER stress (194). 
Activation of JNK and attenuation of AKT also contributed to NO-dependent β cell 
apoptosis (195). 
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Lastly, cytokines are not always detrimental factors to β cells, as a very low dose 
of IL-1β was found to stimulate insulin secretion (196). In a recent study, in both mouse 
and human islets in response to metabolic stress during obesity but not late stage 
diabetes, IL-1β promoted insulin secretion through increasing the RRP of insulin 
granules, thus playing a role in compensatory hypersecretion (197).  
c. Mitochondrial dysfunction, AMP-activated protein kinase (AMPK) and 
oxidative stress 
Mitochondria also play a critical role in maintaining β cell function and survival. 
The commonly seen insults during the development of T2D, including GLT and 
inflammation, usually induce mitochondrial dysfunction that closely interacts with other 
stressors and causes activation of deleterious downstream pathways. Indeed, in T2D 
humans and in rodent models, mitochondria in β cells become disconnected, swollen, 
and shorter (198). 
Mitochondria play a central role in metabolism–secretion coupling by generating 
ATP.  In pancreatic β cells from individuals with T2D, uncoupling protein 2 (UCP-2) up-
regulation was observed, leading to an impairment of respiratory-chain activation, loss of 
mitochondrial ATP production, and altered insulin secretion (199). Similarly, depletion of 
mitochondrial Ca2+ uptake 1 (MICU1) or mitochondrial Ca2+ uniporter (MCU) reduced 
mitochondrial Ca2+ uptake in response to glucose, thus diminishing ATP production and 
insulin secretion (200).  In the meantime, reactive oxygen species (ROS) produced by 
the mitochondria during nutrient catabolism also regulates insulin secretion. Due to the 
constant challenge under nutrient surfeit conditions, β cells can generate large amounts 
of ROS from non-enzymatic glycosylation reactions, the mitochondrial electron transport 
chain, and the hexosamine pathway (201). Chronic accumulation of mitochondrial free-
25 
radical production has been regarded as a result of diminished electron transport 
occurring when ATP production exceeds cellular energy demand. Although acute and 
low grade ROS potentiates insulin secretion (202), prolonged elevation of ROS triggers 
apoptosis (198). Given the fact that the β cell has a relatively low expression level of 
antioxidant enzymes, β cells are rather vulnerable to ROS induced cell damage (203, 
204). Indeed, cadaveric donor islets from individuals with T2D demonstrate elevated 
ROS compared to individuals with normal glycemia (205). Although, it should be 
mentioned that unlike skeletal muscle, in response to ROS stress, global changes in 
oxidative metabolism gene expression was not observed, suggesting a unique ROS 
response in β cells (206).     
The most well-studied downstream pathways activated upon ROS exposure are 
the JNK, p38 MAPK, and protein kinase C (PKC) pathways (114). Activation of these 
kinases was found to precede the decrease in Pdx-1 and insulin gene expression, 
indicating the potential pathological role of ROS in β cell dysfunction in diabetes (201, 
207).  Mitochondria dysfunction in response to pro-inflammatory cytokines also occurred 
in islets isolated from diabetic rodent samples, which showed significantly decreased 
expression of Sirtuin (SIRT)3.  SIRT3 is a key regulator of ROS production and has anti-
inflammatory effects, while overexpression of SIRT3 induced elevation of ROS and 
apoptosis in cultured β cells (208).  
As the most critical energy sensing node in the cell, AMPK regulates energy 
balance by activating ATP synthase. When cellular energy levels are low, signified by an 
increased ADP/ATP ratio, AMPK is activated. Whereas the AMPK activators metformin 
and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) are commonly used drugs 
to improve insulin resistance in peripheral tissues, chronic activation of AMPK was found 
to cause obesity and impair β cell function (209). This finding suggests that long-term 
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AMPK activation can have adverse metabolic consequences. Indeed, AMPK was also 
activated under certain stress models like inflammation or oxidative stress induced by 
ROS or reactive nitrogen species (RNS), and may contribute to downstream detrimental 
effects (210). Clearly the AMPK pathway plays a critical role in β cell function, but 
remains poorly understood.  One of the specific aims of my dissertation research has 
been to better characterize the role of AMPK in β cell Ca2+ homeostasis.  
d. The unfolded protein response (UPR) and ER stress 
A key downstream pathway activated by GLT and pro-inflammatory cytokines is 
the unfolded protein response (UPR). The UPR is a protective cascade that activates a 
series of transcription, translation, and degradation events to increase ER folding 
capacity, limit delivery of new proteins to the ER, and increase clearance of unfolded 
proteins (211-213). ER stress is a broad term that encompasses a series of complex 
cellular signaling events that occur in response to the accumulation of misfolded proteins 
in the ER lumen (154, 214). Initially, an adaptive UPR activates signaling cascades 
initiated by the dissociation of BiP, a calcium-dependent ER chaperone, from inositol-
requiring enzyme 1 α (IRE1α), activating transcription factor 6 (ATF6) and PKR-like ER 
kinase (PERK). This will trigger three distinct signalling cascades that synergize to 
restore ER health and homeostasis. IRE1α activates alternative splicing of Xbp-1 mRNA. 
Spliced Xbp-1 is a transcriptional activator of genes whose products regulate protein 
maturation, folding and ER export. IRE1α also works by degrading mRNAs, thereby 
limiting the delivery of new proteins to the ER. ATF6 is a basic leucine zipper 
transcription factor, which translocates to the Golgi after dissociation from BiP where it is 
cleaved and activated by Site-1 and Site-2 proteases.  ATF6 subsequently translocates 
to the nucleus and binds the ER stress response element in the promoter of ER 
chaperones genes like calnexin, calreticulin, and BiP. The final arm of the UPR involves 
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activation of PERK, which phosphorylates eIF2α. Phosphorylated eIF2α inhibits 80s 
ribosome assembly and therefore decreases global protein synthesis. ER-associated 
degradation (ERAD) is also activated, which helps clear the ER of misfolded proteins 
(215, 216).  While the goal of the adaptive UPR is to restore cellular and ER 
homeostasis, sustained activation of the UPR has detrimental effects.  The transition to 
sustained activation is referred to as ER stress, and ultimately results in apoptosis and 
cell death. Sustained activation of IRE-1 and PERK activates JNK, pro-apoptotic BCL-2 
family members like BAX and PUMA (217), and increases activation of C/EBP 
Homology Protein (CHOP) (218) and cleaved caspase-3 (211, 212, 219-221).  
In response to the increasing demand for insulin due to peripheral insulin 
resistance under conditions of obesity, the β cells are driven to considerably higher 
levels protein synthesis and folding. This increased activity will trigger the UPR, which is 
initially adaptive.  However, the process can culminate in terminal ER stress (211, 222, 
223). Indeed, ER stress activation has been described in both rodent and human models 
of T2D (41, 212, 213, 224). Several key molecules involved in the UPR pathway have 
been studied using genetically modified mouse models to unravel their effects in 
regulating β cell fate under stress conditions. Overexpression of BiP in β cells protects 
against ER stress-induced cell death (225), while knocking out BCL2L11 (Bim) or PUMA 
was able to delay glucotoxicity-induced cell death (226). Cellular inhibitor of apoptosis 
protein-1 (cIAP1) was found to be protective from lipotoxicity-induced ER stress in β 
cells by increasing the degradation of CHOP (227). Together, these studies highlight the 
critical role that ER health plays in maintaining β cell survival, and demonstrate that a 
failure of adaptive UPR can contribute to apoptosis and β cell loss. 
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e. Calcium dyshomeostasis  
The precise control of intracellular and extracellular Ca2+ gradients is critical in 
mediating a number of aspects of β cell function including stimulus-secretion coupling, 
insulin maturation, insulin granule transportation, exocytosis, proliferation, and activation 
of the UPR (30, 154, 228, 229). Dysregulated Ca2+ homeostasis is found in both the 
cytosol and organelles under T2D conditions (230). It was also found that as animals 
age, the function of the β cell deteriorates in parallel with impaired Ca2+ mobilization 
(231). It  is well accepted that cellular Ca2+ overload or perturbation of intracellular Ca2+ 
compartmentalization can cause cytotoxicity, triggering either apoptotic or necrotic cell 
death (232). This usually manifests as a chronic elevation of cytosolic Ca2+, depletion of 
ER Ca2+, or both.  
First, cytosolic Ca2+ overload from abnormal Ca2+ efflux from the ER leads to 
sustained elevations in cytosolic Ca2+, which can cause apoptosis (233, 234). Both 
inborn and environmental factors may contribute to this phenomenon. For example, 
mutation in the gene WFS1 encoding wolframin induced an elevation in cytosolic Ca2+ 
levels, altered ER function, and caused cell death. The WFS1 mutation is responsible for 
wolfram syndrome, which has the symptoms of DM, as well as optic atrophy, and 
deafness (77). Other Ca2+ regulators might also contribute to Ca2+ dysregulation and ER 
stress. In a recent study, a mouse model with mutated RyR2 with higher Ca2+ 
transportation rate caused activation of ER stress and mitochondrial dysfunction in β 
cells (235). Another study suggested that IP3R is involved in ER stress activation 
potentially due to the subcellular localization of IP3R in mitochondria-associated 
membranes (MAMs), which are areas of close contact between the ER and the 
mitochondria, thus controlling Ca2+ homeostasis in both organelles (198). Although 
neither RyR nor IP3R seem to have a direct function in insulin biosynthesis, RyR2 also 
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serves as a protective factor to prevent calpain 10-dependent apoptosis (236). On the 
contrary, gain-of-function studies show that overexpression of PMCA2 or NCX1 leads to 
ER Ca2+ depletion with subsequent ER stress as well as lower proliferation and higher 
apoptosis (237).  
Secondly, environmental factors like GLT, pro-inflammatory cytokines, oxidative 
stress and ER stress also cause Ca2+ dyshomeostasis. Acute treatment of isolated 
mouse islets with  NEFAs elevated basal cytosolic Ca2+ levels, but only slightly affect 
glucose-stimulated Ca2+ increases (phase 1 amplitude) (238). Long term palmitate 
treatment (24 h) in human and mouse cultured β cells depletes ER Ca2+ and 
subsequently induces ER stress (239). Chronic GLT also significantly decreases Ca2+ 
mobilization in response to glucose and GSIS (240).  
This Ca2+-related apoptotic response occurs partially via an increase in  the 
permeability of the outer mitochondrial membrane (233), leading to cytochrome c 
release and activation of a caspase cascade. In this regard, caspase 3, one of the most 
important caspase family members, plays a critical role in the process of apoptosis via 
DNA fragmentation and chromatin condensation. Caspase 3 has also been found to 
cleave IP3R and PMCA leading to further disruptions of Ca2+ homeostasis (241). 
Treatment with the SERCA inhibitor, thapsigargin, induced ER Ca2+ leakage and 
decreased the expression of BiP, the ER chaperone protein that contributes to apoptosis 
(242). Increased cytosolic Ca2+ can also cause hyper-activation of calpain-2, followed by 
the cleavage of α-spectrin, leading to β cell death during T2D (243).  
f. Rescue strategies of ER stress and calcium dyshomeostasis 
Ca2+-dependent apoptosis and dysfunction can be partially rescued by 
decreasing cytosolic Ca2+ levels, replenishing ER Ca2+ and improving of the folding 
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capacity of the ER. Ca2+ channel blockers that prevent the inward flux of Ca2+ from the 
extracellular space showed protective effects in β cell survival that were mediated by 
decreasing stress-induced TXNIP expression (244). Hepatic ER stress was rescued by 
SERCA2b overexpression or by treatment with a small molecule allosteric activator (245, 
246). Chemical chaperones are small molecules that are non-selective in their ability to 
stabilize misfolded proteins and facilitate their proper folding. 4-phenylbutyric acid (PBA) 
and tauroursodeoxycholic acid (TUDCA) are most commonly used, and are the only two 
chemical chaperones approved by US Food and Drug Administration (FDA) for use in 
humans (247). PBA was found to significantly reduce activated caspase-12 and pro-
apoptotic CHOP protein levels in the liver of animals treated with an ER stress inducer 
(248). In pancreatic β-cells, PBA was also found to prevent the development of the 
aberrant ER morphology, which is characterized by a localized punctate pattern 
associated with ER stress, leading to an improved GSIS (248). TUDCA was shown to 
improve overall islet function by decreasing protein aggregates and restoring expression 
of UPR mediators (249).  
g. Monitoring Ca2+ in live cells and tissues 
As discussed above, intracellular Ca2+ homeostasis (especially ER Ca2+ levels) 
plays critical roles in a number of aspects of the β cell in both physiological and disease 
states.  Therefore, it is essential to measure the mobilization of Ca2+ in different 
organelles in response to certain stimuli or conditions.  Although technically challenging, 
there are several different methods available to evaluate Ca2+ concentrations in these 
different cell compartments in cultured cells and tissues (250). There are mainly 3 types 
of cellular Ca2+ indicators: photoproteins, chemical Ca2+ indicators/fluorescent dyes, and 
fluorescent protein-based biosensors (251).  
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The photoproteins, mainly aequorin and genetically modified versions of aequorin, 
were initially discovered in jellyfish and were used to provide the first visualization of 
Ca2+ waves. These experiments required single cell injection and covered a wide Ca2+ 
range from 40 nM to 40 µM. Monitoring aequorin does not require laser excitation, thus 
minimizing the problems of autofluorescence, photo-bleaching and high background. 
However, the lack of fluorescence makes this method incompatible with high-resolution 
imaging microscopy. Furthermore, the low intensity of signal, over-sensitivity to Ca2+ 
concentration fluctuations and difficulty of equilibration have led to decreased use of 
aequorin (252).  
The main fluorescent dye used to monitor Ca2+ concentrations is based on the 
Ca2+ chelator bis-(o-aminophenoxy)-ethane-N,N,N9,N9-tetra acetic acid (BAPTA). There 
are a number of commercially available chemical dyes that have different affinities to 
Ca2+ and varying spectral properties. The most commonly used fluorescent dye is Fura-
2-acetoxymethyl ester (Fura-2 AM). This dye has 3 useful features: 1) high Ca2+ affinity 
(thus more suitable for cytosolic Ca2+ measurement which is at nM level); 2) ratiometric 
measurements that allow a very accurate quantification of Ca2+ concentration that is 
corrected for uneven dye loading, dye leakage, photo-bleaching and changes in cell 
volume; and 3) the dye is provided in a acetoxymethyl ester chemical form, which is 
membrane permeable and thus doesn’t require an invasive loading procedure (253).  
The removal of the ester group by intracellular esterases prevents the dye from leaking 
back out of the cell.  
Despite the convenience of chemical fluorescent dyes, one of the biggest 
disadvantages of this technique is that it cannot clearly differentiate Ca2+ concentrations 
in different organelles. However, the last type of Ca2+ indicator, genetically encodable 
Ca2+ indicators or Ca2+ sensitive fluorescent protein, have been developed to be 
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specifically expressed in certain organelles. Recently, the most commonly used of these 
is the cameleon-based fluorescent protein D1ER (254). By improving Ca2+ affinity and 
inserting the insulin promoter, D1ER was engineered to be D4ER which allows for 
exclusive expression in the ER of β cells (255). Our studies, as well as those of others 
have used this approach to detect changes in ER Ca2+ concentrations using this probe 
(255, 256).   
Recently, an improved Ca2+ indicator, Twitch-1, was developed and has been 
used to monitor Ca2+ levels in T cells. Due to the exceptionally wide dynamic range of 
this indicator, it can be used to study different compartments of cell at the same scale 
(257).  The Twitch and D1/D4ER biosensor probes generate signals through Förster 
Resonance Energy Transfer (FRET).  The sensor unit of biosensor probes contains 
linked donor and acceptor fluorophores, and conformational changes allow FRET 
between the donor to the acceptor fluorophore.  The most accurate methods for 
detecting changes in FRET signals measure the change in the donor fluorescence 
lifetime that results from the quenching by the acceptor (258). This can be monitored at 
a microenvironment level in individual cells by fluorescence lifetime imaging microscopy 
(FLIM) (259).  
1.4 SERCA Structure, Function, and Regulation in β Cells 
1.4.1 Protein structure, kinetic features and different isoforms of SERCA 
In mammals, there are 3 different SERCA genes (ATP2A1, ATP2A2 and 
ATP2A3 encoding the proteins SERCA1, 2 and 3) with at least 14 isoforms arising as a 
result of alternative splicing. Tissue-specific expression patterns suggest cell specific 
function of different isoforms and also indicate patterns of temporal expression during 
development (260). The SERCA protein contains 10-11 transmembrane α-helix domains 
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and 3 additional major domains that extend into the cytosolic compartment. These 
domains include the P domain, where phosphorylation occurs and the N domain, which 
serves as the site of nucleotide-binding. These two domains form the catalytic site where 
ATP is hydrolyzed. The A domain, or actuator domain, is involved in the transmission of 
major protein conformational changes during each catalytic cycle (261).  
There are two major conformational statuses of SERCA pumps: the E1 form has 
relatively high Ca2+ affinity, while the E2 confirmation has a lower affinity. The function of 
SERCA is highly ATP dependent, and each catalytic cycle starts with the E1 
conformation, where 2 Ca2+ molecules are bound in the absence of ATP (E1Ca2).  
When ATP binds to the N domain, it triggers a conformational change and 
phosphorylation of the P domain (E1Ca2→ E1PCa2).  This event decreases Ca2+ affinity 
and drives the movement of Ca2+ into the ER lumen (E1PCa2 → E2PCa2 →  E2P), thus 
favoring hydrolysis of the phosphoenzyme (E2P → E2) and completion of the cycle 
(262).  
Among SERCA isoforms, there are two general categories.  The first includes 
isoforms mainly found in muscle and includes SERCA1 and SERCA2a.  The second 
category consists of non-muscle isoforms and includes SERCA2b and SERCA3. These 
various isoforms not only have different tissue and developmental expression profiles, 
but the affinity and ATP turnover rates also vary. SERCA2b and SERCA3 are rather 
unique among all the isoforms in terms of kinetic features (263). Compared to the 
structure of SERCA2a (264), SERCA2b uniquely contains an extra 11th transmembrane 
α-helix at the C-terminus, which stabilizes the Ca2+ bound confirmation and provides the 
highest Ca2+ affinity among all isoforms as well as the slowest ATP turnover rate (44). 
On the other hand, SERCA3 has the lowest affinity for Ca2+ with a higher optimum pH. 
The other isoforms have nearly identical kinetic features.  
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We have previously shown SERCA2b to be the most prevalent isoform 
expressed in the mouse pancreatic islet. The second most abundant isoform is SERCA3, 
which is expressed at about 50% of the level of SERCA2b.  The alternatively-spliced 
isoform, SERCA2a, is expressed at nearly 100-fold lower levels compared to SERCA2b 
(265). Among all the isoforms, the role of SERCA3 in the pancreatic β cell has been 
previously investigated in a series of papers by Patrick Gilon and colleagues.  Using 
whole-body SERCA3 knockout mice, this group showed that lack of SERCA3 alone 
does not lead to increased cytosolic Ca2+ in islets and is not sufficient to disturb glucose 
homeostasis or impair insulin secretion (266). Rather, SERCA3 KO mice exhibited 
normal glucose tolerance without overt evidence of ER stress. SERCA3 ablation also did 
not affect basal cytosolic Ca2+ levels or the initial glucose-induced Ca2+ response within 
islets (266). Following glucose stimulation, SERCA3 null islets exhibited a higher 
amplitude of Phase 2 [Ca2+]i oscillations, consistent with impaired ER Ca2+ uptake that 
interestingly led to increased insulin secretion (255). Together, these data suggest that a 
lack of SERCA3 is insufficient in itself to alter glucose homeostasis or impair insulin 
secretion in mice. Rather, SERCA3 has a regulatory role in Ca2+ oscillation. 
1.4.2 Transcriptional and post-translational regulation of SERCA2  
There is some evidence suggesting that SERCA2 serves as a stress response 
gene and is part of a compensatory response to protect against ER stress.  The 
SERCA2 promoter contains multiple ER stress response elements.  While it has not 
been studied in the β cell, ER stress was found to upregulate SERCA2 transcription and 
activity in adrenal gland phaeochromocytoma cells (267, 268) potentially through an 
ATF6 binding site found in SERCA promoter (269).  In response to acute ischemia, 
SERCA2a has been shown to be upregulated in cardiac muscle cells, suggesting an 
adaptive response to hypoxia (270). Similarly, ischemia induced SERCA2b mRNA up-
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regulation in cortical area 1 (CA1) and CA3 hippocampal neurons in a hypoxia-inducible 
factor 1-α (HIF-1α) dependent manner (271).   
In contrast, we and others have demonstrated diminished β cell SERCA2b 
expression in human and rodent models of T1D and T2D, resulting in Ca2+ 
dyshomeostasis, impaired insulin secretion, activation of ER stress signaling pathways, 
and impaired β cell survival (77, 256, 265, 272, 273). In addition to its role in β cells, 
SERCA2b has also been shown to be decreased in liver in obesity and metabolic 
syndrome, leading to hepatic ER stess (274).  
A major goal of my work in this dissertation has been to define the pathways 
leading to altered β cell expression of SERCA2b under pro-inflammatory and diabetic 
conditions.  We and others have shown that loss of SERCA2b mRNA and protein is 
partially NO-dependent (272, 275).  We have also identified peroxisome proliferator-
activated receptor γ (PPARγ) and Pdx-1 as transcriptional regulators of SERCA2. 
Specifically, the binding ability of PPARγ to SERCA2 promoter decreased due to under 
phosphorylation of S273 site, and loss of Pdx-1 expression under diabetic conditions 
which all contribute to down-regulation of SERCA2b (256, 265).  
SERCA2 expression was also lower in infarcted myocardium tissues, and a 
number of miRNA species were found to be elevated in these tissues as well. Through 
bioinformatics strategies, miRs predicted to target SERCA2 mRNA (miR-199a for 
SERCA2b, miR-140 for both isoforms, and miR-574 for SERCA2a) were discovered. 
However, this observation was based on correlation and the direct dependency of these 
miRNA species and SERCA2 expression regulation need to be confirmed (276).  
In addition to transcriptional mechanisms, post-translational mechanisms of 
SERCA2 regulation have been described. Under high-glucose induced oxidative stress, 
SERCA2 protein undergoes a number of post-translational modifications that affect both 
catalytic activity and protein stability, including nitration at the cysteine-674 site which is 
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thought to be an early marker in heart failure (261, 277). Nitration at tyrosine-294 and 
tyrosine-295 were also observed in SERCA2 in skeletal muscle, and this phenomenon 
has been correlated with an aging-induced decrease in SERCA activity (278). 
1.4.3 SERCA dysfunction and human disease 
Mutations in genes encoding isoforms of SERCA have been associated with 
different human diseases. Mutations in in ATP2A1 (encoding SERCA1) cause the 
autosomal recessive condition, Brody’s myopathy (274).  Mutations in ATP2A2 
(encoding SERCA2) underlie an autosomal dominant disorder, Darier disease with the 
symptom of vulnerability in both keratinocytes and neuronal cells (279).  As an animal 
model of Darier disease, whole body SERCA2 haploinsufficent mice have been 
developed that have higher susceptibility to squamous cell tumors and heart dysfunction 
(280, 281). Indeed, SERCA2a expression is reduced in heart failure in humans (282). As 
for diabetes, SERCA2b was lower in insulin resistant macrophage foam cells, which 
might contribute to the development of atherosclerosis (283). In streptozotocin (STZ)-
induced diabetic rats, SERCA2a was significantly decreased in the soleus muscle with 
peripheral neuropathy (284). However, to date, the in vivo role of SERCA2 in the 
maintenance of metabolic homeostasis especially in regulating β cell function remains 
incompletely characterized. One of the specific aims in my thesis will cover this area. 
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1.5. Hypothesis and significance 
My central hypothesis is that SERCA2b plays a critical role in the maintenance of 
β cell function and that loss of SERCA2b expression and activity plays a pivotal role in 
the failed β cell compensatory response and stimulated insulin secretion during the 
development of T2D.  
1.5.1 Post-translational regulation of SERCA2 under pro-inflammatory condition  
In chapter 2, I have defined the mechanisms through which NO signaling impacts 
SERCA2b expression in the pancreatic β cell. I demonstrated that NO-mediated loss of 
SERCA2b expression and activity is primarily due to post-translational mechanisms and 
identified AMPK as one of the pathways that synergize with NO to regulate β cell ER 
Ca2+ homeostasis under inflammatory conditions. These results provided a novel role for 
chronic AMPK activation in the regulation of SERCA2b in the β cell. 
1.5.2 In vivo role of SERCA2 in the β cell under metabolic stresses 
In chapter 3, I determined how SERCA2b regulates whole body glucose 
homeostasis, β cell integrity and insulin secretion. I showed that SERCA2b deficiency 
impaired whole body glucose homeostasis and islet integrity due to the failure of β cells 
to compensate for metabolic stress during obesity.  Abnormal Ca2+ management in the 
context of SERCA2 deficiency led to altered β cell proliferation, secretory function, and 
survival while SERCA2 overexpression or the application of a small molecule allosteric 
activator reduced effects on β cell function and survival. These discoveries have 
provided key information about the global metabolic phenotype arising from SERCA2b 
deficiency and suggest this pathway may be a potential therapeutic target for diabetes.  
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CHAPTER TWO 
NO Stress and Activation of AMPK Impair β Cell SERCA2b Activity and  
Protein Stability 
2.1 Introduction 
Loss of β cell SERCA2b expression under pro-inflammatory and diabetic 
conditions is thought to occur, at least partially, through nitric oxide (NO) dependent 
mechanisms (272).  However, whether NO-mediated loss of SERCA2b expression and 
activity is primarily due to a transcriptional or post-translational mechanism is not clear.  
Moreover, the downstream pathways that synergize with NO-signaling to alter 
endoplasmic reticulum Ca2+ have not been fully defined.  In this regard, the activity and 
fidelity of ATPases including SERCA are highly dependent on overall cellular energy 
status. SERCA pumps are estimated to consume 7%-25% of total cellular ATP whereas 
ADP levels are closely correlated with SERCA activity (285-287). A well-recognized 
downstream effect of pro-inflammatory cytokine signaling and NO production is an 
impairment of mitochondrial function, leading to altered ATP synthesis (288).  Whereas 
these effects contribute to β cell dysfunction and apoptosis, they also lead to activation 
of AMPK, which serves as the master sensor of cellular energy status (289).  AMPK has 
a wide range of downstream substrates involved in a variety of processes including 
metabolism, inflammation, as well as ion transport (290). Interestingly, AMPK has been 
shown to directly regulate the activity, expression, and cellular localization of other 
highly-energy consuming protein pumps including the plasma membrane Na+,K+-
ATPase in lung epithelial cells and the H+ ATPase of the intercalated cells of the kidney  
(291-293).  This level of interaction represents one mechanism through which AMPK 
signaling may act to limit energy expenditure under stress conditions.  Interestingly, a 
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recent proteomics study performed in β cells suggested a direct physical interaction 
between AMPK and SERCA2 (294), but a functional relationship between SERCA2b 
and AMPK in the β cell remains unexplored.  
Here, we first aimed to define the mechanisms through which NO signaling 
impacts SERCA2b levels in the pancreatic β cell.  Our second goal was to identify 
pathways that synergize with NO to regulate β cell ER Ca2+ homeostasis under 
inflammatory conditions, hypothesizing a novel role for chronic AMPK activation in the 
regulation of SERCA2b expression and activity.  
2.2 Results 
The pro-inflammatory cytokine IL-1β decreases SERCA2b protein but not mRNA 
stability in both INS-1 cells and isolated rat islets. 
Previous work by our group and others has demonstrated significant 
downregulation of SERCA2b mRNA and protein levels under diabetic conditions (256, 
265, 272, 273).  To determine whether this downregulation was secondary to alterations 
in either mRNA or protein stability, actinomycin and cycloheximide time-course 
experiments were performed under basal conditions and then following treatment with 
the pro-inflammatory cytokine IL-1β. Under control conditions, β cell SERCA2b mRNA 
exhibited a half-life of ~9 h, and IL-1β treatment had no effect mRNA stability (Figure 2A). 
In contrast, SERCA2 protein in INS-1 cells exhibited a half-life of ~24 h under basal 
conditions (Figure 2B and C), and IL-1β significantly reduced the half-life to ~19 h 
(Figure 2B and C). In rat islets, the protein half-life was noted to be ~17 h under control 
conditions, while treatment with IL-1β significantly reduced the half-life to ~11h (Figure 
2D and E). 
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Figure 2. IL-1β treatment decreases SERCA2b protein stability in INS-1 cells and 
isolated rat islets.  
INS-1 cells (A-C) or isolated rat islets (D-E) were treated with 1µM actinomycin or 10µM 
cycloheximide (CHX ) combined with or without 5ng/ml IL-1β for indicated times. Total 
RNA and protein were isolated, and RNA was subjected to real-time qRT-PCR for 
quantification of SERCA2b and actin transcript levels. Immunoblot was performed using 
antibodies against SERCA2 and actin. Protein and mRNA levels were plotted relative to 
levels at time zero, and one phase decay lines for each treatment are shown. Indicated 
comparisons are significantly different (*p < 0.05, ***p < 0.001).  
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NO-dependent downregulation of SERCA2 occurs at the translational level. 
The precise mechanisms underlying NO-mediated alterations in SERCA2b 
expression have not been fully defined.  To this end, INS-1 cells were treated with IL-1β, 
combined with or without the nitric oxide synthase (NOS) inhibitor, NG-monomethyl L-
arginine (L-NMMA), for 24 h(77).  Following IL-1β treatment, loss of both SERCA2b 
protein and mRNA expression was observed (Figure. 3A-C).  L-NMMA treatment was 
able to rescue SERCA2b protein levels (Figure. 3A-B).  However, no effect was 
observed on mRNA expression (Figure. 3C).  These results were confirmed in rat islets 
(Figure. 3D-E), where L-NMMA also resulted in a partial rescue of SERCA2 expression 
following treatment with the pro-inflammatory cytokine IL-1β.  
INS-1 cells were treated next with IL-1β, combined with or without the specific 
NO scavenger Carboxy-PTIO potassium salt (C-PTIO) (Figure. 3F-H) (285). Similar to 
effects observed with L-NMMA, C-PTIO rescued SERCA2 protein but not transcript 
levels (Figure. 3H), suggesting IL-1β-mediated effects on protein expression were 
indeed NO-dependent.  To define whether NO was then sufficient to exert this effect, 
INS-1 cells were treated with the NO donor, S-nitroso-N-acetyl-D,L-penicillamine (SNAP).  
As expected, SNAP decreased SERCA2 protein to a level almost equivalent to that 
observed with IL-1β, while mRNA levels were not significantly altered (Figure. 4A-C). 
Nitrite levels in the culture media were measured under each experimental condition and 
found to increase with IL-1β and SNAP treatment, while L-NMMA exhibited the expected 
effect of decreased nitrite production following IL-1β treatment (Figure. 4D).  Finally, to 
confirm these results in primary cells, rat and cadaveric human islets were treated with 
SNAP.  Consistent with results observed in INS-1 cells, SERCA2 protein expression was 
significantly decreased compared to control conditions in both rat and human islets 
(Figure. 4E-H).  
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Figure 3. NO-dependent loss of SERCA2 expression occurs at a translational level.  
INS-1 cells (A-C, F-H) or isolated rat islets (D-E) were treated with DMSO (CT) or IL-1β 
(IL) combined with or without 0.5 mM of the NOS inhibitor L-NMMA (LN) or 100µM of the 
NO scavenger C-PTIO (CPT) for 24h. Total protein was isolated and immunoblot was 
performed using antibodies against SERCA2, inducible NO synthase (iNOS), and actin.  
Quantitative protein levels of SERCA2 are shown graphically (B, E, G).  Total mRNA 
was isolated from the INS-1 cells treated with CT, LN, IL, IL-LN or IL-CPT, and reverse-
transcribed RNA was subjected to real-time PCR for quantification of SERCA2b and 
actin transcript levels (C). Indicated comparisons are significantly different (**p < 0.01, 
***p < 0.001). 
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Figure 4. Direct effects of NO impair SERCA2 expression at the translational level.  
INS-1 cells, isolated rat islets, or human islets were treated with or without the NO donor 
SNAP (SN) at 300mM for 24h (A-C, E-H). Total protein and mRNA were isolated. 
Immunoblot was performed using antibodies against SERCA2 and actin and quantitative 
protein levels are shown graphically (B, F, H). Reverse-transcribed RNA was subjected 
to real-time PCR for quantification of SERCA2b and actin transcript levels (C). INS-1 
culture media was collected at treatment end, and nitrite concentration were measured 
as described in Materials and Methods (D). Results are statistically different from control 
conditions (B, D, F, H), or indicated comparisons are significantly different (**p < 0.01, 
***p < 0.001). 
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Phosphorylation of AMPKα at Th173 contributes to SERCA2 downregulation at the 
translational level. 
To define novel downstream pathways that synergized with NO to influence 
SERCA2b expression and the overall regulation of ER Ca2+ homeostasis and test 
whether AMPK-mediated effect is involved, INS-1 cells and isolated rat islets were 
treated with IL-1β combined with or without the AMPK inhibitor, compound C (CC). 
Increased levels of phosphorylated AMPKα on Th173 were observed following treatment 
with IL-1β, confirming previous findings that pro-inflammatory cytokines lead to the 
activation of AMPK signaling (289).  Likewise, AMPK activation was blocked by CC 
(Figure. 5A).  Interestingly, CC was also capable of fully reversing IL-1β-mediated loss of 
SERCA2 protein (Figure. 5A-B).  Again, these effects appeared to be primarily restricted 
to protein expression as no significant change in transcript levels were observed (Figure. 
5C). To confirm this relationship, rat islets were treated with IL-1β and CC. Similar to 
results obtained in INS-1 cells, altered SERCA2 protein expression under inflammatory 
conditions was prevented by CC (Figure. 5D-E).  
Next, to study whether direct activation of AMPK was sufficient to decrease 
SERCA2 expression, INS-1 cells were treated with the AMPK agonist 5-aminoimidazole-
4-carboxamide ribonucleotide (AICAR) for 24 h.  Results demonstrated that AICAR 
indeed decreased SERCA2 protein expression to a level similar to that observed with IL-
1β and SNAP treatment (Figure. 5F-G).  Consistent with previous results observed with 
SNAP, mRNA levels were again unaffected (Figure. 5H). Decreased SERCA2 protein 
expression with AICAR mediated-AMPK activation was confirmed in isolated rat islets 
and cadaveric human islets (Figure. 5I-L).  In aggregate, these results indicate that β cell 
SERCA2 protein half-life is significantly altered under inflammatory conditions and loss 
of protein expression occurs concomitantly through NO and AMPK-dependent 
mechanisms.   
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Figure 5. Activation of AMPKα Th173 leads to a loss of SERCA2 protein 
expression. 
INS-1 cells (A-C) or isolated rat islets (C-D) were treated with DMSO (CT) or 5ng/ml IL-
1β (IL) combined with or without 10µM of the AMPK inhibitor compound C (CC) for 24h. 
Total protein was isolated and immunoblot was performed using antibodies against 
SERCA2, phosphorylated AMPKα Th173 (pAMPKα), total AMPK and actin. Quantitative 
protein levels of SERCA2 are shown graphically (B, E). Total mRNA was isolated from 
the INS-1 cells treated with CT, IL and IL-CC, and reverse-transcribed RNA was 
subjected to real-time PCR for quantification of SERCA2b and actin transcript levels (C). 
Next, INS-1 cells, isolated rat islets or human islets were treated with and without AMPK 
activator AICAR (AC) at 2mM for 24h (F-L). Total protein and mRNA were isolated, and 
immunoblot was performed using antibodies against SERCA2, pAMPKα, AMPK and 
actin.  Quantitative protein levels of SERCA2 are shown graphically (G, J, L). Reverse-
transcribed RNA was subjected to real-time PCR for quantification of SERCA2b and 
actin transcript levels (H). Indicated comparisons are significantly different (*p<0.05, **p 
< 0.01, ***p < 0.001), or results are statistically different from control conditions (G, H, J, 
L).   
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NO and activation of AMPK decrease SERCA2 protein stability 
We next addressed whether NO and AMPK-mediated loss of SERCA2 
expression was specifically resulted from alterations in protein stability or not. INS-1 cells 
were co-treated with CHX combined with or without SNAP or AICAR. Results showed 
that treatment with both SNAP and AICAR significantly reduced SERCA2 protein 
stability (Figure 6A-C).   
AMPK activation is required for IL-1β-induced downregulation of SERCA2 protein 
INS-1 cells, rat islets, and human islets were next transduced with an HA-tagged 
AMPK-DN or luciferase expressing control adenovirus to further test the relationship 
between AMPK signaling and SERCA2 expression.  Reduced AMPK signaling with the 
AMPK-DN construct was confirmed by reductions in the level of phosphorylated Acetyl-
CoA carboxylase (pACC), a key downstream target of AMPK (Figure. 7A,C-D) (290). 
Virally transduced INS-1 cells and rat islets were treated with IL-1β whereas human 
islets were treated with a combination of IL-1β, INF-γ, and TNF-α. Interestingly, the 
AMPK-DN adenovirus increased basal expression of SERCA2 in rat and human islets 
(Figure. 7C-D). Moreover, in AMPK-DN transduced INS-1 cells (Figure. 7A-B), rat islets 
(Figure. 7C), and human islets (Figure. 7D), cytokine-induced reductions in SERCA2 
protein expression were prevented. Taken together, these data demonstrate that AMPK 
is necessary for pro-inflammatory-induced downregulation of SERCA2 protein 
expression. 
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Figure 6. SERCA2 protein stability is decreased by NO-dependent signaling and 
AMPK activation.  
INS-1 cells were treated with DMSO (CT) or 10µM cycloheximide (CHX) combined with 
or without 300 mM of SNAP (SN) or 2mM AICAR (AC) for 24 h. A-B, Total protein was 
isolated; immunoblot was performed using antibodies against SERCA2 and actin. C. 
Quantitative protein levels of SERCA2 are shown graphically.  Indicated comparisons 
are significantly different (**p < 0.01).  
  
48 
 
Figure 7. AMPK activation is required for IL-1β-induced loss of SERCA2 protein 
expression. 
INS-1 cells (A-B), isolated rat islets (C) or non-diabetic cadaveric human islets (D) were 
transduced with an HA-tagged AMPK dominant negative (AMPK-DN or DN) or control 
adenovirus (Luci or Lu) before 24-h treatment with or without 5 ng/ml IL-1β (for INS-1 
cells and rat islets) or a combination of 5ng/ml IL-1β, 1 ng/ml TNF-α and 100 ng/ml IFN-γ 
in human islets. Total protein was isolated, and immunoblot was performed using 
antibodies against SERCA2, pAMPKα, total AMPKα, phosphorylated ACC(pACC), total 
ACC, HA, and actin. B. Quantitative protein levels of SERCA2 in INS-1 cells are shown 
graphically.  Indicated comparisons are significantly different (**p < 0.01).  
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AMPK activation modulates IL-1β induced iNOS expression and it is required in 
SNAP induced down-regulation of SERCA2. 
To determine the relationship between AMPK and NO signaling following 
cytokine stress, INS-1 cell and rat islets were treated with CC concurrently with IL-1β.  
Interestingly, iNOS protein expression was significantly decreased in the presence of CC 
(Figure. 8A-C).  Similarly, decreased iNOS gene expression was observed in INS-1 cells 
treated with CC and IL-1β (Figure. 8H).  To rule out nonspecific effects from the use of 
pharmacological inhibitors, INS-1 cells and rat islets were again transduced with the 
AMPK-DN or control adenovirus and subsequently treated with IL-1β. In AMPK-DN 
transduced INS-1 cells and rat islets, a similar reduction in iNOS expression was noted 
following IL-1β treatment, and reduced iNOS gene expression was observed (Figure. 
8D-F, I).  This relationship was confirmed by measuring nitrite production, where results 
showed that IL-1β-mediated increases in nitrite production were dramatically reduced 
with compound C and partially reduced in INS-1 cells transduced with the AMPK-DN 
adenovirus (Figure. 8G). To define whether AMPK activation was then necessary for 
SNAP-induced loss of SERCA2 expression, INS-1 cells were treated with SNAP 
combined with or without CC. Interestingly, SERCA2 protein expression was indeed 
preserved by CC treatment (Figure. 9A-B).  
In aggregate, our data showed that AMPK is activated under inflammatory 
conditions and IL-1β-mediated reductions in SERCA2 expression were partially AMPK-
dependent.  However, our results also showed that AMPK signaling led to an 
amplification of NO-mediated inflammatory responses in the pancreatic β cell. To 
investigate this further, INS-1 cells were treated with 1 mM and 2 mM of AICAR for 24 h.  
Results showed that AICAR decreased IκBα protein levels in a dose-dependent manner, 
suggesting that AMPK activation leads to reduced retention of NFκB in the cytosol 
(Figure. 9C-D).   
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Figure 8. AMPK activation modulates IL-1β induced iNOS expression. 
A-I, AMPK activation modulates IL-1β-induced iNOS expression and is required for 
SNAP-induced downregulation of SERCA2. INS-1 cells or isolated rat islets 
were treated with dimethyl sulfoxide (DMSO) (CT), CC, 5 ng/ml IL-1β (IL) with or without 
CC (IL-CC) or transduced with an HA-tagged AMPK-DN or DN or control adenovirus 
(Luci or Lu) before treatment with or without 5 ng/ml IL-1β. A and D, Total protein was 
isolated, and immunoblot was performed using antibodies against iNOS and actin. B, C, 
E, F, Quantitative protein levels of iNOS are shown graphically. G, INS-1 culture media 
was collected at treatment end, and nitrite concentration measurement was performed. 
H and I Total mRNA was isolated from INS-1 cells, and reverse-transcribed RNA was 
subjected to real-time PCR for quantification of iNOS and actin transcript levels. 
Indicated comparisons are significantly different (*p<0.05, **p<0.01 and ***p<0.001)  
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Figure 9. AMPK activation is required in SNAP induced down-regulation of 
SERCA2. 
A-D, INS-1 cells were treated with DMSO (CT), 300 mM of SNAP (SN) combined with or 
without 10 μM of CC, or AICAR at the indicated doses for 24 h. Total protein was 
isolated, and immunoblot was performed using antibodies against SERCA2, pAMPKa, 
IκBα and actin. Quantitative protein levels of SERCA2 (B) or IκBα (D) are shown 
graphically. Indicated comparisons are significantly different (*p<0.05, **p<0.01 and 
***p<0.001)  
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AMPK activation alters β cell Ca2+ homeostasis and SERCA2 activity. 
To explore the functional effects of pro-inflammatory signaling on β cell Ca2+ 
homeostasis, the FLIPR Calcium 6 Assay Kit was used to measure basal cytosolic Ca2+ 
levels and Ca2+ mobilization from the ER in response to the indicated compounds 
(Figure. 10A-D).  Experiments were performed both in the presence (Figure. 10A-B) and 
absence of extracellular Ca2+ (Figure. 10C-D), and showed that IL-1β, SNAP, and 
AICAR significantly increased basal cytosolic Ca2+ levels and decreased ER Ca2+ levels 
(as assessed by changes in the ∆F/F0 ratio following caffeine treatment).  Notably, the 
effects of IL-1β were reversed by co-treatment with L-NMMA.  In aggregate, these 
results demonstrate that pro-inflammatory NO-mediated signaling as well as AMPK 
activation alter β cell Ca2+ compartmentalization, resulting in decreased ER Ca2+ levels 
and a reciprocal increase in basal cytosolic Ca2+. 
Next, INS-1 cells were incubated with the Ca2+ dye Fura-2AM. Basal Ca2+ levels 
within the cytosolic compartment and changes in Ca2+ transit following ER Ca2+ depletion 
with caffeine were analyzed according to the schematic indicated in Figure. 11A. To 
provide an additional estimate of SERCA pump activity, the slope of the change in the 
Fura-2AM ratio following withdrawal of caffeine and closure of RyR was calculated using 
linear regression (Figure 11B). INS-1 cells were then treated with AICAR for 0, 3, and 16 
h. Whereas 3 h of AICAR treatment did not alter the ΔF/F0 ratio (Figure 11C), AICAR 
treatment for 16 h significantly reduced the ΔF/F0 ratio.  Interestingly, both short-term (3 
h) and long-term (16 h) AICAR led to decreased Ca2+ reuptake following removal of 
caffeine. Together, these results were consistent with observed changes in SERCA2b 
expression and suggest that AMPK activation impairs SERCA activity (Figure. 8D), while 
chronic AMPK treatment leads to a reduction in ER Ca2+ storage.   
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Figure 10. IL-1β, SNAP and AICAR alter β cell Ca2+ homeostasis. 
To assess cytosolic Ca2+ levels, Calcium 6 fluorescence were measured as described 
under Materials and Methods. A-D. Calcium 6 measurements in INS-1 cells pre-treated 
with DMSO (CT), 5 ng/ml IL-1β (IL) combined with or without 0.5 mM L-NMMA (LN), 300 
mM SNAP (SN) or 2 mM AICAR (AC) for 24 h. Indicated comparisons are significantly 
different (*p<0.01 ***p<0.001).   
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 Figure 11. Direct activation of AMPK impairs SERCA2 activity. 
To further assess cytosolic Ca2+ levels, fura-2/AM fluorescence ratios were measured as 
described under Materials and Methods. INS-1 cells were pre-treated with DMSO (CT) 
or 2 mM AICAR for 3 h or 16 h. (A) Schematic illustrating the calculation of ΔF/F0 ratios 
from fura-2/AM imaging experiments.  The Ca2+ clearance rate was used as an estimate 
of SERCA2 activity and was analyzed using linear regression to calculate the slope of 
the fura-2/AM ratio following withdrawal of caffeine.  (B) Representative trace from 
untreated INS-1 cells (CT) and INS-1 cells treated with AICAR for 3 h or 16 h. (C-D) 
Quantitative results of the ΔF/F0 ratio and slope from INS-1 cells untreated (CT) or 
treated with AICAR for 3 h or 16 h.  Indicated comparisons are significantly different 
(*p<0.01 ***p<0.001).   
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Inhibition of iNOS and AMPK protect INS-1 cells from IL-1β-induced apoptosis 
Finally, to determine whether the observed rescue of SERCA2 expression also 
influenced cell survival, INS-1 cells were treated with L-NMMA, C-PTIO or CC alone or 
combined with IL-1β, and the ratio of cleaved caspase 3 to total caspase 3 expression 
was measured by immunoblot.  Cleaved caspase 3 expression was significantly 
increased with IL-1β treatment, but reduced to control levels in the presence of L-NMMA, 
C-PTIO, and CC (Figure. 12A-B).  Next, the CellTiter-Glo Luminescent Cell Viability 
Assay was employed in INS-1 cells treated with the same combination of compounds 
above as well as SNAP and AICAR alone.  Viability was similarly reduced with IL-1β, 
SNAP, and AICAR, while L-NMMA, C-PTIO, and CC were able to rescue IL-1β-mediated 
cell death (Figure. 12C), indicating that loss of β cell survival under pro-inflammatory 
conditions occurs through NO- and AMPK-dependent pathways and is closely correlated 
with changes in SERCA2b expression and activity.  
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Figure 12. Inhibition of iNOS and AMPK protect INS-1 cells from IL-1β induced 
apoptosis 
A-C. INS-1 cells were treated with DMSO (CT) or 5 ng/ml IL-1β (IL) combined with or 
without 0.5 mM of the NOS inhibitor L-NMMA (LN) or 100 µM of the NO scavenger C-
PTIO (CPT) for 24 h. Total protein was isolated, and immunoblot was performed using 
antibodies against cleaved caspase 3, total caspase 3 and actin. B. Ratios of the relative 
expression of cleaved caspase 3 to total caspase 3 are shown graphically.  C. Cell 
viability assays were performed as described in the Materials and Methods section; 10 % 
Triton treatment for 10 min was used as positive control for cell death. Indicated 
comparisons are significantly different (***p < 0.001). 
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Figure 13. Overall model of NO-and AMPK-dependent down-regulation of SERCA2 
Together, our data suggest that under pro-inflammatory and diabetic conditions, 
activation of NO-mediated signaling in the pancreatic β cell leads to an alteration in 
cellular energy status and activation of the master cellular energy sensor AMPK.  The 
convergence of NO and AMPK signaling leads to a reduction of SERCA2b activity and 
alters SERCA2b protein stability, leading to reduced SERCA2b expression.  The 
reduction of SERCA2b causes dysregulation of intracellular and ER Ca2+ homeostasis 
that ultimately leads to a loss of β cell function and survival.  Whereas NO may initiate 
the activation AMPK, our data also suggest that AMPK amplifies the inflammatory 
response of the pancreatic β cell.   
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2.3 Discussion 
We and others have demonstrated diminished β cell SERCA2b levels in human 
and rodent models of T1D and T2D (51-53), with alterations in SERCA2b expression 
leading to impaired Ca2+ homeostasis and insulin secretion, activation of ER stress 
signaling pathways, and altered β cell survival (68, 256, 265, 273). Cardozo et al 
previously described a role for pro-inflammatory cytokines and induction of the NFκB-
dependent gene, inducible nitric oxide synthase (iNOS), in loss of β cell SERCA2b 
mRNA and protein expression (295).  However, whether NO-mediated changes in 
SERCA2b expression and/or activity are primarily due to a transcriptional or post-
translational mechanism remains unexplored.  Moreover, the downstream pathways that 
synergize with NO to alter endoplasmic reticulum Ca2+ in the β cell have not been fully 
defined.   
To address this, we first determined the half-life of SERCA2 protein and mRNA 
under basal and pro-inflammatory conditions. Data from both INS-1 cells and rat islets 
demonstrate that treatment with the cytokine IL-1β led to decreased SERCA2 protein 
stability without significantly altering mRNA half-life. Interestingly, treatment with the 
iNOS inhibitor, L-NMMA, rescued SERCA2 protein stability under inflammatory 
conditions, but was unable to restore mRNA levels, suggesting divergent regulation of 
mRNA and protein expression under diabetic and inflammatory conditions. Indeed, our 
previous work is consistent with this notion and has shown that reductions in SERCA2b 
mRNA in models of diabetes may arise instead from loss of key transcriptional 
regulators such Pdx-1 and PPARγ rather than through decreased transcript stability (256, 
265). 
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While temporally regulated and controlled increases in NO have important 
signaling effects in the pancreatic β cell (296), chronically elevated NO generated under 
pathologic conditions plays a central role in cytokine-induced β cell death through a 
variety of effects including, decreased PKB/AKT signaling, potentiation of JNK activation, 
and induction of irreversible DNA damage (194, 297, 298). However, a dominant effect 
of NO is to impair mitochondrial oxidation and altered ATP production, which occurs 
through inhibition of iron-sulphur enzymes such as aconitase (299, 300).  These effects 
are quite potent in the pancreatic islet, where treatment with IL-1β is associated with at 
least a four-fold reduction in ATP levels (301).    
AMPK is a multisubstrate, heterotrimeric serine/threonine kinase with a role in a 
variety of cellular pathways.  AMPK is activated directly through phosphorylation by one 
of three well-described upstream kinases, liver kinase B1 (LKB1), Ca2+ /calmodulin-
dependent protein kinase kinase (CaMKK), or Transforming growth factor β-activated 
kinase 1(TAK1), while a second major pathway of activation involves allosteric 
modulation by AMP and ADP.  Thus AMPK activity increases in response to any process 
that decreases ATP levels, including NO-induced stress, hypoxia, and glucose 
deprivation (302).  Interestingly, AMPK has also been shown to regulate ion transport as 
well as cellular ATPase activity.  In this regard, Alzamora et al. demonstrated direct 
phosphorylation of the kidney vacuolar H+-ATPase by AMPK, and this modification led to 
changes in cellular localization and decreased activity of the protein pump (293). 
Similarly, hypoxia in alveolar cells leads to AMPK-triggered inactivation and endocytosis 
of the basolateral Na+,K+-ATPase, with resulting impairments in lung fluid clearance 
(291).   
With these relationships in mind, we investigated a novel link between SERCA2b 
and AMPK signaling, hypothesizing that restraint of SERCA activity may be one way that 
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AMPK alters β cell energy expenditure under inflammatory conditions. ATPases are 
energetically expensive to maintain and SERCA pumps alone have been estimated to 
consume upwards of 7%-25% of cellular ATP under normal conditions (285-287).  In 
support of our hypothesis, a recent interactome study involving large-scale affinity 
purification -mass spectrometry of the AMPKα subunit was performed in INS-1 β cells, 
and identified SERCA2 as a potential AMPKα binding partner (294).  Indeed, our results 
show that chronic AMPK activation decreases SERCA2 protein expression in INS-1 cells, 
rat islets, and human islets through a mechanism involving a reduction in protein half-life. 
Moreover, pharmacologic as well as genetic inhibition of AMPK rescued cytokine-
induced loss of SERCA2 expression and cytokine-induced cell death.  We explored a 
functional effect of this relationship using intracellular Ca2+ imaging and demonstrate that 
both short and long-term AMPK activation alters SERCA activity levels, leading 
reductions in ER Ca2+ with a reciprocal increase in cytosolic Ca2+. 
While beneficial metabolic effects of AMPK have been well described in 
peripheral tissues including the liver and skeletal muscle (302), the effects of AMPK 
activation in the β cell remain somewhat controversial.  Divergent effects of AMPK 
appear to be dependent on both the level of activation as well as the chronicity of 
activation in experimental models.  In the short term, AMPK stimulates insulin secretion 
and may promote recovery from stress.  In contrast, chronic or long-term activation, 
similar to paradigm applied in our study, has been linked to impairments in insulin 
secretion as well as altered β cell survival (303-305). Indeed, a pro-apoptotic role for 
AMPK has been described in other cell types and is linked with a variety of mechanisms 
including cell cycle arrest, activation of p53, and JNK signaling (306).  Specifically in the 
β cell and consistent with our findings, previous studies suggest that pharmacologic 
activation of AMPK with AICAR or virally induced constitutive activation of AMPK 
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induced islet and β cell death, while a dominant negative form of AMPK was capable of 
protecting against cytokine-induced apoptosis (289, 307).  Similarly, constitutive 
activation of AMPK within transplanted islets decreased insulin secretion and β cell 
survival in STZ-treated diabetic mice (308).  
Our study raises a number of interesting questions for future investigation. While 
we suggest an initiating role for ATP depletion in our model, there are likely other 
pathways that lead to AMPK activation under inflammatory conditions.  In fact, a study 
by Gordon et al. showed that NO modulates AMPK activity in the β cell through an IRE-1 
dependent mechanism as part of the unfolded protein response (304).  It is also 
tempting to speculate that increased cytosolic Ca2+ resulting from initial perturbations in 
SERCA activity may augment AMPK activation through a CaMKK-dependent pathway, 
though this remains to be tested.  Likewise, an interesting relationship uncovered by our 
data is that pharmacologic inhibition of AMPK with compound C and treatment with the 
AMPK-DN construct attenuated IL-1β-induced iNOS gene and protein expression. This 
result was further confirmed by measuring nitrite concentrations in the culture media.  
Similar to our results, Santos and colleagues have shown that knockdown of AMPK in 
MIN-6 β cells blocked cytokine or lipopolysaccharide induced expression of iNOS (305, 
309).  These data and ours suggest that AMPK is not only activated by NO signaling but 
may also be responsible for amplifying the inflammatory response. AICAR has 
previously been shown to activate NFκB in a neuroblastoma cell line through 
degradation of IκBα (306).  We investigated this possibility in INS-1 cells, and similarly 
found that AICAR treatment led to a dose-dependent reduction in IκBα expression in the 
pancreatic β cell. Notably, a recent study discovered that a mouse model with chronic 
activation of AMPK has also been found to induce obesity and impair β cell function (209) 
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In aggregate, these data provide evidence for a novel pathway that links NO and 
AMPK signaling with altered β cell Ca2+ homeostasis and provide additional insight into 
the regulation of β cell survival under inflammatory conditions that typify both Type 1 and 
Type 2 diabetes.  
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CHAPTER THREE 
SERCA2 Deficiency Impairs Pancreatic β Cell Function in Response to  
Diet-Induced Obesity 
3.1 Introduction 
During the development of T2D and in the face of advancing peripheral insulin 
resistance, the β cell undergoes a functional and proliferative compensatory response to 
increase insulin output and maintain euglycemia.  The ability of the β cell to continue in 
this extended state of compensation is finite for a substantial proportion of individuals, 
and the typical evolution to T2D is characterized by loss of pancreatic β cell function, 
mass, and possibly identity by de-differentiation and trans-differentiation (147, 310).  
To define the role of SERCA2 in the regulation of whole body glucose 
homeostasis during this compensatory state, we utilized whole body SERCA2 
heterozygous mice (S2HET) challenged with HFD, and performed metabolic analysis on 
these animals.  Here, we show that SERCA2 deficiency leads to glucose intolerance, 
which occurs secondary to altered β cell insulin secretion, reduced β cell proliferation, 
and increased β cell ER stress.  In contrast, no differences in weight gain, insulin 
sensitivity or peripheral insulin signaling were observed between S2HET and WT 
controls after HFD.  Finally, we show that modulation of SERCA2 activity with a small 
molecule allosteric activator rescued ER stress and restored ER Ca2+ levels, and 
prevented β cell apoptosis. Together, these data suggest a critical role for SERCA2 
activity and the maintenance of β cell ER Ca2+ homeostasis in the compensatory 
response to diet-induced obesity.  Importantly, our results raise the possibility that 
persons with Darier White Disease may have an increased susceptibility to metabolic 
disease. 
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3.2 Result 
Whole body SERCA2 haploinsufficiency leads to impaired glucose tolerance in 
response to diet-induced obesity  
To directly assess the role of SERCA2 in the maintenance of in vivo glucose 
homeostasis, S2HET mice bred congenic on a C57BL6/J background and WT 
littermates controls were studied. To determine the role of SERCA2 in the compensatory 
response to diet-induced obesity, S2HET and WT mice were challenged with a HFD 
containing 45% of kilocalories from fat beginning at 8 weeks of age. Islet SERCA2 levels 
remained suppressed by the expected 50% before and after HFD, and no changes in 
SERCA3 protein or mRNA expression were observed (Figure 14A-C).  Temporal 
patterns of weight gain and the percentage of lean and fat mass were identical between 
groups (Figure 14D-E). However, compared to WT HFD-fed controls, S2HET mice 
demonstrated significantly higher fasting blood glucose levels and lower fed insulin 
levels (Figure 14F-G). HFD-fed S2HET and WT controls were next challenged with 
either oral or intraperitoneal glucose (OGTT and IPGTT), administered at a dose of 
2g/kg of body weight.  Glucose tolerance in both S2HET and WT mice during IPGTT 
was significantly altered after HFD. Furthermore, in response to both IP and oral glucose 
challenge, S2HET mice exhibited significantly increased glucose excursions and 
reduced glucose tolerance compared to WT controls, as measured by the area under 
the curve analysis of IPGTT and OGTT (Figure. 15A-D).   
While insulin tolerance tests revealed significantly decreased insulin sensitivity 
after HFD in both S2HET and WT, no differences were observed between genotypes 
(Figure 16A-B).  Levels of AKT phosphorylation at serine 473 in the liver, epididymal 
adipose tissue, and gastrocnemius muscle were measured under basal conditions and 
following acute insulin injection.  No differences were observed between genotypes 
(Figure 16C-E).  
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Figure 14. S2HET mice exhibit glucose dyshomeostasis following HFD.  
SERCA2 haploinsufficient mice (HET) and wild-type littermate controls (WT) were fed 
high fat diet (HFD) containing 45% of kilocalories from fat for 16 wks starting at 8 wks of 
age. A-C, Protein and RNA were isolated from HET and WT islets before (normal chow 
or NC) and after 16 wks of HFD (WT-HFD and HET-HFD).  Immunoblot analysis was 
performed using antibodies against SERCA2, SERCA3, and Actin (A).  Quantitative 
SERCA2 protein levels are shown graphically (B).  Reverse-transcribed RNA was 
subjected to real-time quantitative RT-PCR (qRT-PCR) to measure SERCA2b and 
SERCA3 transcript levels (normalized to Actb) (C). D-E, Longitudinal changes in body 
weight were measured, and DEXA analysis was performed in HET and WT mice at the 
start and after 16 wks of HFD. F, Blood glucose in 6 hr-fasted WT and HET mice before 
and after 16 wks of HFD. G, Random-fed serum insulin levels following 16 wks of HFD. 
Indicated comparisons are significantly different; *, p<0.05; ***, p<0.001. 
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Figure 15. S2HET mice manifest impaired glucose tolerance following HFD 
challenge.  
S2HET and WT were fed HFD containing 45% of kilocalories from fat for 16 weeks 
starting at 8 weeks of age. I.P. glucose tolerance tests (IPGTT) (A-B) or oral glucose 
tolerance tests (OGTT) (C-D) were performed before or after 16 wks of HFD treatment in 
HET and WT mice; area under the curve (AUC) analysis is shown graphically. Open 
squares, WT mice after HFD; solid squares, S2HET mice after HFD; Open circles, WT 
mice before HFD; solid circles, S2HET mice before HFD.  Results are displayed as 
means ± S.E.M; n=at least 8 per group. Indicated comparisons are significantly different; 
*, p<0.05; ***, p<0.001. 
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Figure 16. HFD-fed S2HET and wild-type mice exhibit comparable insulin 
sensitivity and levels of insulin induced AKT phosphorylation in adipose, liver, 
and skeletal muscle.  
A-B, Insulin tolerance tests were performed before and after 14 weeks of HFD, and the 
AUC analysis is shown graphically. Open squares, WT mice after HFD; solid squares, 
S2HET mice after HFD; open circle, WT mice before HFD; solid circle, S2HET mice 
before HFD Adipose (C), liver (D) or skeletal muscle (E) protein homogenates were 
obtained from saline (basal) or insulin injected S2HET and WT fed HFD for 16 wks.  
Immunoblot analysis was performed using antibodies against phospho-AKT (ser473), 
total AKT, and actin. Relative protein levels are shown graphically. Results are displayed 
as means ± S.E.M; n=6 per group; n.s. indicates that no significant differences were 
observed between groups. Indicated comparisons are significantly different; **, p<0.01  
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SERCA2 deficiency results in impaired GSIS  
  Initial analysis of HFD-fed S2HET mice revealed hyperglycemia, reduced serum 
insulin levels, and impaired glucose tolerance without apparent alterations in insulin 
sensitivity or adiposity, suggesting a defect in β cell function.  To define further the β cell 
phenotype associated with in vivo SERCA2 deficiency, insulin levels were measured in 
S2HET and WT controls after a 5 hour fast (time 0) and 10 min after i.p. glucose 
injection. In response to glucose challenge, serum insulin levels were significantly lower 
in HFD-fed S2HET mice compared to those of HFD-fed WT controls (Figure 17A). 
Similar to in vivo findings, results from ex vivo glucose stimulated insulin secretion 
assays performed in isolated islets revealed a significant decrease in fractional insulin 
secretion from HFD-fed S2HET islets (Figure 17B).   
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Figure 17. SERCA2 deficiency leads to impaired β cell insulin secretion. 
A, Serum insulin levels were measured following a 5 hr fast and 10 minutes after i.p. 
injection of 2 mg/kg glucose in S2HET(HET) and WT fed HFD for 16 weeks.  Open 
square, wild-type mice; solid square, S2HET mice. B, Islets were isolated from HFD-fed 
HET and WT mice. Glucose stimulated insulin secretion was measured and normalized 
to total insulin content. Results are displayed as the means ± S.E.M; n = at least 4 
independent experiments for each group.  Indicated comparisons are significantly 
different; *, p<0.01; ***, p<0.001.   
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SERCA2 deficiency results in impaired islet Ca2+ homeostasis  
Next, Fura-2 AM calcium imaging experiments were performed in islets isolated 
from normal chow and HFD-fed S2HET and WT mice.  Baseline cytosolic Ca2+ levels 
were increased after HFD-fed in genotypes, while S2HET mice exhibited a significantly 
larger increase in baseline Ca2+ (Figure 18A-C). Similarly, HFD induced a significant 
delay in the onset of steady state cytosolic Ca2+ oscillations in response to glucose 
(phase 1 duration).  Compared to WT under both normal chow and HFD conditions, 
S2HET islets exhibited a further lengthening of the phase 1 duration. (Figure 18D), while 
the initial glucose stimulated Ca2+ response (labeled as the phase 1 amplitude) was also 
significantly reduced in HFD-S2HET islets (Figure 18B, E). The amplitude of the 
oscillatory response (phase 2 amplitude) was not significant different between groups 
(Figure 18F). Notably, Ca2+ response to KCl was also impaired (Figure 19A-B), 
suggesting these defects did not arise as a result of altered glucose sensing.    
FLIM was next used to directly monitor ER Ca2+ in dispersed normal chow-fed 
WT and S2HET islets that had been transduced with the ER-directed calcium biosensor 
D4ER adenovirus and then treated with or without GLT   Results revealed lower ER Ca2+ 
levels in S2HET β cells that was exacerbated by chronic treatment with 25 mM glucose 
and 500 µM BSA-conjugated palmitate (Figure 19C-D).   
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Figure 18. Islets isolated from HFD-fed S2HET mice exhibit impaired cytosolic Ca2+ 
homeostasis and oscillation in response to glucose. 
Islets isolated from normal chow or HFD-fed WT (solid line) and S2HET (dashed line) 
mice were loaded with Fura-2AM and calcium imaging performed.  A and C, 
Representative [Ca2+]i recording of islets following stimulation with 15 mM glucose. B. 
Quantitation of the relative basal [Ca2+]i (F0) in WT and HET islets. D, Phase 1 duration 
in WT and S2HET(HET)  islets. E,  Quantitation of the phase 1 [Ca2+]i amplitude.  F, 
Quantitation of the average Phase 2 [Ca2+]i amplitude from five continuous oscillatory 
cycles per islet. Results are displayed as mean ± S.E.M, and indicated comparisons are 
significantly different. *, p<0.05; ***, p<0.001; n=26 islets from 3 biological replicates per 
group.  
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Figure 19. Islets isolated from HFD-fed S2HET mice exhibit impaired ER Ca2+ 
homeostasis. 
Islets isolated from normal chow or HFD-fed WT (solid line) and S2HET (dashed line) 
mice were loaded with Fura-2AM and calcium imaging performed.  G. Representative 
[Ca2+]i recording of islets following stimulation with 30 mM KCl. H. Quantitation of the 
phase 1 [Ca2+]i amplitude in response to KCl.  I-J. Dispersed islets were transduced with 
a D4ER adenovirus and FLIM was used to measure endoplasmic reticulum Ca2+. I, 
Representative lifetime map with lookup table indicating donor lifetime in ns (scale bar is 
10 µm) and average donor lifetime (J) in WT and S2HET β cells treated with or without 
GLT (n=at least 10 cells were quantitated per treatment group). Results are displayed as 
mean ± S.E.M, and indicated comparisons are significantly different. *, p<0.05; ***, 
p<0.001; n=26 islets from 3 biological replicates per group.  
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SERCA2 deficiency results in impaired islet insulin production, processing and 
packaging 
To test whether insulin biosynthesis was impaired, total insulin content and 
insulin mRNA levels were measured in isolated islets from HFD-fed animals. The levels 
of both were found to be significantly decreased in S2HET islets compared to WT 
controls (Figure 20A-B). Compared to HFD-fed wild-type controls, HFD-fed S2HET mice 
exhibited a nearly 2-fold increase in the serum proinsulin/insulin ratio (Figure 20C), 
suggesting a parallel decrease in proinsulin maturation.   
Insulin granule morphology was next assessed by quantitative analysis of islet 
electron micrographic images.  Typical mature insulin granules were defined according 
to previously published protocols and exhibited a dense homogenous core with a clear 
halo, while immature granules exhibited an empty or lighter core and the absence of a 
defined halo (Figure 20D) (311). The percentage of immature granules was nearly 2-fold 
higher in HFD-fed S2HET mice compared to controls. In addition, S2HET islets 
displayed a significantly higher percentage of rod-like granules, indicating defective 
insulin crystallization and packaging (Figure 20E).  Paired with defects in insulin 
processing, both PC1/3 protein and transcripts levels were decreased in islets isolated 
from HFD-fed S2HET mice (Figure 20F-H). These observations in the S2HET islets are 
confirmed and extended by western blot performed in SERCA2 knockout INS-1 cells 
(described in Figure 26A-C, below).        
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Figure 20. S2HET mice fed HFD exhibit impaired insulin biosynthesis 
Islets were isolated from HFD-fed S2HET(HET) and WT mice. A, Total islet insulin 
content was normalized to islet DNA content. B, Ins1 and Ins2 transcript levels were 
measured by qRT-PCR and normalized to Actb levels. C, Serum proinsulin levels were 
measured after 16 weeks of HFD in WT and S2HET mice.  Results were expressed as 
the ratio of serum proinsulin to insulin; n=5 biological replicates for panel A-C. D-E, Islets 
from 3 WT or S2HET mice before and after 16-wks HFD were pooleed and analyzed by 
electron microscopy. Representative EM images of β cells and insulin granule 
morphology from HFD-fed mice are shown.  Panel E indicates quantitiative analysis of 
20 images per group. Scale bar = 1 µm. F-H, Protein and RNA were isolated from islets 
of WT and HET mice fed 16-wks HFD.  Immunoblot analysis was performed using 
antibodies against PC1/3 and actin. Quantitative protein and transcripts levels are shown 
graphically.  Results are displayed as mean ± S.E.M. The indicated comparisons are 
significantly different. *, p<0.05; **, p<0.01; ***, p<0.001. 
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SERCA2 haploinsufficient mice demonstrated lower β cell proliferation, reduced β 
cell mass, and increased β cell death in response to HFD 
  Next, β cell mass was quantitated at 8 weeks of age prior to HFD initiation, and 
following 16 weeks of HFD exposure. At baseline, there was no significant difference in 
β cell mass between chow-fed S2HET and WT control mice. In contrast, after HFD, 
S2HET mice demonstrated significantly lower β cell mass than that of age-matched 
controls (Figure 21A-B). However, no significant difference in the number of alpha cells 
per islet was noted between groups after HFD (Figure 21C-D). To assess β cell 
proliferation, pancreatic sections were stained with antibodies against insulin and 
proliferating cell nuclear antigen (PCNA).  Double-positive cells were counted and the 
results indicated a significant reduction in the percentage of proliferating β cells in 
S2HET mice in response to HFD (Figure 22E-F).  Finally, to assess β cell death, droplet 
digital PCR was used to measure circulating levels of unmethylated cell-free insulin DNA 
at baseline and during HFD treatment (312). At baseline, S2HET mice exhibited a trend 
of higher unmethylated DNA levels compared to WT controls.  After 8 weeks, S2HET 
mice had significantly higher circulating levels of unmethylated insulin DNA, while no 
difference between groups was noted after 17 weeks of HFD (Figure 22G).  
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Figure 21. S2HET mice fed HFD exhibit decreased β cell mass 
A, Representative images of insulin immunohistochemistry in pancreata harvested from 
HFD-fed S2HET(HET) and WT.  B, β cell mass was quantified in WT and HET mice 
before and after HFD treatment. C and D, Representative images of insulin and 
glucagon immunofluorescence in pancreata harvested from HFD-fed WT and HET mice. 
Scale bar = 50 µm. Quantification of the number of alpha cells per islet is shown 
graphically. Results are displayed as means ± S.E.M; n=at least 4 biological replicates 
per group. The indicated comparisons are significantly different. *, p<0.05; **, p<0.01. 
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Figure 22. S2HET mice fed HFD exhibit decreased β cell proliferation with 
increased cell death 
A-B, Quantification of the percentage of PCNA-positive β cells. C, Random fed serum 
was collected from WT and HET mice before and during HFD feeding at indicated times. 
Levels of circulating unmethylated mouse Ins2 DNA levels were measured by ddPCR 
and depicted as Log (copies/µL). Open symbols, wild-type mice; solid symbols, S2HET 
mice. NC=normal chow at 8 wks of age.  Results are displayed as means ± S.E.M; n=at 
least 4 biological replicates per group, while n values are indicated by scatterplot in 
Panel C.  The indicated comparisons are significantly different. *, p<0.05; **, p<0.01. 
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SERCA2 deficiency increases ER stress pathways 
Our results suggest that SERCA2 haploinsufficiency reduced the ability of 
pancreatic islets to compensate for the metabolic challenge of HFD, which occurred 
secondary to impaired β cell secretory function, decreased β cell proliferation, and 
increased β cell death. Next, ER morphology was analyzed from electron micrographic 
images of islets isolated from HFD-fed S2HET and WT mice.  In contrast to the regularly 
spaced stacks of ER sheets observed in β cells from WT mice, analysis of S2HET β 
cells revealed swollen and fragmented ER morphology (Figure 23A). Expression of 
genes encoding proteins involved in ER stress signaling, including Grp78, Dnajc3, 
Hsp90b1 and Pdia4 were significantly increased, while the spliced Xbp-1 to total Xbp-1 
ratio (S/T Xbp-1) was higher in S2HET islets (Figure 23B).  To confirm these findings, 
islets were next isolated from chow-fed S2HET and WT control mice and treated ex vivo 
with 25 mM glucose and 500 µM palmitate for 24 h (glucolipotoxicity; GLT) to mimic HFD 
conditions. Expression of Grp78, Dnajc3, Hsp90b1 and Pdia4 were increased at 
baseline in S2HET islets and further elevated in response to GLT stress, while the 
spliced Xbp-1 to total Xbp-1 ratio was significantly increased in GLT-treated S2HET 
islets compared to levels observed in WT controls (Figure 23C).  
To confirm a β cell-autonomous defect with SERCA2 deficiency, a SERCA2 
knockout INS-1 832/13 cell line (S2KO) was generated.  While SERCA2b mRNA and 
SERCA2 protein were reduced in S2KO cells, no significant alterations in RyR2 or IP3R 
expression were observed (Figure 24A-B). SERCA3 transcript levels were decreased by 
~40%, but no significant alteration in SERCA3 protein expression was seen. Consistent 
with expression analysis performed in S2HET islets, expression of genes involved in ER 
stress signaling, including Grp78, Dnajc3, Hsp90b1, Pdia4 and S/T Xbp-1, were 
significantly elevated in S2KO INS-1 cells under basal conditions and in response to 
GLT stress (Figure 24C).   
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Figure 23. S2HET islets exhibit higher ER stress  
A, Islets from 3 WT or 3 S2HET mice fed HFD for 16 weeks were pooled, fixed and 
analysed by electron microscopy. Representative images of the β cell ER structure are 
shown. B, Islets were isolated from 16-week HFD-fed S2HET mice or WT controls (n=5-
6).  Reverse-transcribed RNA was subjected to qRT-PCR to measure Grp78, Dnajc3, 
Hsp90b1, Pdia4, spliced Xbp-1, total Xbp-1 and Actb transcript levels.  C, Islets freshly 
isolated from 10-week-old male mice fed normal chow were treated with or without 25 
mM glucose + 500 µM palmitate (GLT) for 24 h. Reverse-transcribed RNA was subjected 
to qRT-PCR to measure indicated gene transcripts levels (n=9 biological replicates 
analysed over three individual experiments). Results are displayed as means ± S.E.M.  
The indicated comparisons are significantly different. *, p<0.05; **, p<0.01; ***, p<0.001.   
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Figure 24. Cultured β cells with SERCA2 deficiency exhibit higher ER stress  
A, Immunoblot analysis was performed in S2KO using antibodies against SERCA2, 
SERCA3, and actin.  B, Reverse transcribed RNA isolated from S2KO and WT INS-1 
cells was subjected to real-time quantitative RT-PCR for quantification of SERCA2b and 
SERCA3, RyR2 and IP3R3, and results were normalized to Actb transcript levels. C, 
Reverse transcribed RNA isolated from S2KO and WT INS-1 cells treated with or without 
GLT for 24 h was subjected to real-time quantitative RT-PCR for quantification of 
indicated transcript levels. D-F. Protein and RNA were isolated from WT and S2KO INS-
1 cells.  Immunoblot analysis was performed using antibodies against PC1/3 and actin. 
Quantitative protein and transcripts levels are shown graphically.  Results are displayed 
as means ± S.E.M.  The indicated comparisons are significantly different. *, p<0.05; **, 
p<0.01; ***, p<0.001.   
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SERCA2b reconstitution protects against β cell death and Ca2+ dyshomeostasis in 
response to ER and glucolipotoxic stress 
S2KO and WT cells were next treated with tunicamycin (TM) to perturb protein 
folding by inhibiting protein glycosylation. Under control conditions and in response to 
TM, cleaved caspase-3 protein levels were significantly higher in S2KO cells (Figure 
25A-B).  Similarly, S2KO cells exhibited decreased cell viability with TM and GLT-
induced stress (Figure 25C).  To test whether SERCA2 reconstitution was sufficient to 
reverse these effects, cells were transduced with SERCA2b or LacZ expressing 
adenovirus (Figure 25D). SERCA2b overexpression improved viability in both WT and 
S2KO cells treated with GLT and TM (Figure 25E-F).   
Calcium imaging experiments were next performed in S2KO and WT cells that 
had been treated with GLT or TM and transduced with either SERCA2b or LacZ 
expressing adenovirus. Carbachol and caffeine were used to stimulate IP3 and RyR-
mediated ER Ca2+ release, respectively, providing an indirect assessment of ER Ca2+ 
storage (275).  Results were analyzed as the change in Ca2+ (ΔF) in response to 
caffeine or carbachol, normalized to the baseline cytosolic Ca2+ level (F0). At baseline, 
S2KO cells exhibited a significant reduction in the ΔF/F0 ratio.  The ΔF/F0 ratio was 
further decreased in both GLT and TM-treated WT and S2KO cells, while SERCA2b 
overexpression rescued the carbachol and caffeine response in S2KO cells and the 
carbachol response in WT cells (Figure 26A-B). Similar to results obtained in S2HET 
islets, FLIM performed in S2KO cells also revealed a significant reduction in the ER Ca2+ 
concentration (Figure 26C). Next, INS-1 cells were treated with CDN1163, which is a 
small molecular allosteric SERCA2 activator. FLIM analysis revealed that CDN1163 was 
capable of increasing ER Ca2+ within 2 h with no further increases observed after 24 h.  
Interestingly, CDN1163 was also able to partially rescue TM-induced cleaved caspase-3 
expression (Figure 26D-F.)  
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Figure 25. SERCA2 KO β cells manifest increased susceptibility to stress-induced 
death 
A-B, WT and S2KO INS-1 cells were treated with or without 10 µM of tunicamycin (TM) 
for 24 hrs. Immunoblot analysis was performed using antibodies against cleaved 
caspase-3, total caspase-3 and Actin. Quantitative protein levels are shown graphically. 
C, WT and S2KO INS-1 cells were treated under control conditions (CTR) or exposed to 
GLT or TM for 24 hrs, and viability was measured using the CellTiter-Glo assay.  Results 
were normalized to results obtained in WT cells under control conditions. D-F, SERCA2b 
was overexpressed (S2OE) via adenoviral transduction in WT and S2KO INS-1 cells and 
then treated with GLT or TM for 24 hrs. Immunoblot analysis was performed using 
antibodies against SERCA2 and Actin: (D); CellTiter-Glo viability tests were performed in 
WT (E) and S2KO cells (F).  Results were normalized to cells transduced with LacZ virus 
under control conditions.  SERCA2b was overexpressed via adenoviral transduction in 
WT (WT-OE) and S2KO (KO-OE) INS-1 cells followed by exposure to GLT for 24 hrs. 
Immunoblot analysis was performed using antibodies against cleaved caspase-3 and 
Actin, and quantitative protein levels are shown graphically. Results are displayed as 
means ± S.E.M, and indicated comparisons were significantly different. *, p<0.05; **, 
p<0.01; ***, p<0.001;   
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Figure 26. SERCA2 KO β cells manifest impaired Ca2+ storage 
A and B, To assess cytosolic Ca2+ levels, Calcium 6 fluorescence was measured under 
Ca2+ free conditions. C and D, INS-1 cells were transduced with a D4ER adenovirus and 
FLIM was used to measure endoplasmic reticulum Ca2+. Shown is the average donor 
lifetime in WT and S2KO INS-1 cells (C) or WT INS-1 cells treated with 10 µM CDN1163 
for 2 or 24 hrs (D), n=at least 10 regions of interest per cell type or treatment. E and F, 
WT and S2KO INS-1 cells were treated with or without TM combined with or without 10 
µM CDN1163 for 24 hrs. Immunoblot analysis was performed using antibodies against 
cleaved caspase-3 and Actin, and quantitative protein levels are shown graphically. 
Results are displayed as means ± S.E.M, and indicated comparisons were significantly 
different. *, p<0.05; **, p<0.01; ***, p<0.001;   
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3.3 Discussion 
In rodent and human models of diabetes, acquired loss of β cell SERCA2 
expression and activity under inflammatory conditions has been correlated with altered β 
cell Ca2+ homeostasis, reduced insulin secretion, and impaired survival.  Furthermore,   
SERCA2 restoration has been shown to improve these parameters (256, 265, 275).  
However, whether in vivo deficiency of SERCA2 is sufficient to impair systemic 
metabolic function and/or β cell health has never been addressed. Because 
homozygous loss of SERCA2 is embryonically lethal (282), we used the S2HET model 
to analyzed β cell function following a HFD challenge. Our results show that SERCA2 
deficiency leads to impaired glucose tolerance and hyperglycemia upon metabolic 
challenge. In contrast, S2HET and WT mice exhibited indistinguishable patterns of 
weight gain, body composition, and systemic and tissue-specific insulin sensitivity.  This 
is notable since in vitro experiments have shown that SERCA2 and SERCA1 interact 
with IRS-1 and IRS-2 in skeletal muscle in an insulin dependent manner (313).  Previous 
studies have shown that SERCA2 overexpression in the liver or treatment with 
CDN1163 attenuated liver ER stress and improved in diabetic models (245, 246).  
However, our data suggest that the glucose intolerance observed in HFD-fed S2HET 
mice does not arise from perturbations in adiposity or insulin sensitivity.  Rather, we 
conclude that SERCA2 deficiency leads to an impaired β cell compensatory response to 
diet-induced obesity.  In support of this conclusion, we have shown that SERCA2 
deficiency leads to decreased β cell insulin production, insulin secretion, and 
proliferation, which likely arise because of increased β cell ER stress, and perturbed β 
cell Ca2+ signaling.   
The ER is a key intracellular Ca2+ store with the intraluminal Ca2+ concentration is 
estimated to be at least several orders of magnitude higher than cytosolic. The SERCA 
family of ATPases is the only known group of transporters tasked with Ca2+ uptake into 
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the ER lumen, while ER Ca2+ release occurs via RyRs and IP3Rs, which become 
activated in response to specific ligands or intracellular signaling pathways (314, 315). 
To date, the in vivo role of IP3R in the pancreatic β cell has yet to be studied. However, a 
single point mutation in the RyR, leading to an unregulated ER Ca2+ leak, results in 
decreased insulin secretion and impaired glucose tolerance as well as β cell ER stress 
and mitochondrial dysfunction (235). These results and our study emphasize a pivotal 
role for ER Ca2+ homeostasis in the maintenance of β cell function and health. 
Among all the 14 isoforms within SERCA family, SERCA3 function in the islet 
has been previously investigated in series of elegant studies by Gilon and colleagues 
with whole-body deletion of SERCA3. Under chow-fed conditions, SERCA3 KO mice 
exhibited normal glucose tolerance without overt evidence of ER stress. SERCA3 
ablation also did not affect basal cytosolic Ca2+ levels or the initial glucose-induced Ca2+ 
response within islets (266). Following glucose stimulation, SERCA3 null islets exhibited 
a higher amplitude of Phase 2 [Ca2+]i oscillations, consistent with impaired ER Ca2+ 
uptake that interestingly led to increased insulin secretion (255). Whereas SERCA3 mice 
have never been challenged with diet-induced obesity, somewhat limiting direct 
comparisons, our results still suggest non-overlapping functions for the two isoforms.  
We show that SERCA2 haploinsufficiency leads to increased basal cytosolic Ca2+ levels, 
impaired glucose and KCl-stimulated Ca2+ responses, and a delayed onset and reduced 
amplitude of glucose-induced Ca2+ oscillations. This suggests a broader role for 
SERCA2 and the ER Ca2+ pool in patterning β cell Ca2+ architecture, independent of 
glucose sensing and ATP generation. In contrast to SERCA3 null islets, perturbations in 
Ca2+ signaling in SERCA2-deficient islets were sufficient to impair glucose-stimulated 
insulin secretion both in vivo and ex vivo.  Notably, no compensatory up-regulation of 
SERCA3 protein expression in either our mouse model or in the clonal SERCA2 KO β 
cell line was observed.   
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SERCA2 deficiency also had a significant impact on β cell ER function and health.  
S2HET islets exhibited altered ER morphology and increased expression of genes 
involved in ER stress signaling, while SERCA2 deficient INS-1 cells were more 
susceptible to glucolipotoxic and tunicamycin-induced cell death. Previous work has 
shown that ER stress in β cell results in insulin mRNA degradation through activation of 
IRE1α, whereas PERK activation suppressed insulin translational (316-318). Consistent 
with these studies, islet insulin mRNA and protein levels were decreased and circulating 
levels of insulin were lower in S2HET mice compared to WT controls. Given that the 
S2HET mice have global SERCA2 deficiency including liver, the impaired glucose 
tolerance we observed might be partly due to hepatic ER stress in response to obesity, 
as was shown in a previous study (246). However, further studies are necessary using 
our model system to determine the specific contributions of hepatic function to impaired 
glucose tolerance.    
In addition, S2HET islets also exhibited impaired insulin processing and 
decreased insulin granule maturation after HFD. Proteolytic cleavage of proinsulin into 
mature insulin requires the activity of prohormone convertase (PC) 1/3, PC 2 and 
carboxypeptidase E (CPE) within secretory granules.  Ca2+ is also required to direct PC 
1/3 into dense core secretory granules (319), while further serving as an essential 
cofactor for both PC 1/3 and 2 activity (31). The Ca2+ content within secretory granules is 
patterned by ER Ca2+ levels, suggesting a relationship between SERCA2 deficiency and 
convertase enzyme activity (320). A supplemental finding in our study was that PC 1/3 
mRNA and protein expression were also decreased in S2HET islets and S2KO cells in 
both normal chow and after HFD. Regarding this point, a recent study in GLUTag murine 
enteroendocrine cells, which secrete glucagon-like peptide, also revealed decreased 
PC1/3 protein with palmitate-induced ER stress (321). In β cells, a similar effect was 
observed after 7 days of palmitate and oleate treatment in MIN-6 cells (176).  
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Our data also show that SERCA2 deficiency results in decreased β cell 
proliferation in response to diet-induced obesity. Increased SERCA2b expression has 
been shown in several cancer models of unrestrained proliferation, while a number of 
Ca2+-regulated pathways play an important role in β cell proliferation.  For example, 
NFAT and CREB are both activated in response to a rise in cytosolic Ca2+ (322, 323).  
Furthermore, a direct relationship between ER stress and β cell proliferation has been 
suggested by two recent studies.  Pascoe et al. showed that mild ER stress favored β 
cell proliferation (324), while Szabat et al. showed that reduced insulin production 
relieved β cell ER stress and induced β cell proliferation (325).  Precisely how altered 
SERCA2 activity in our model impacts known Ca2+-dependent proliferative pathways and 
integrates with the above studies will be the subject of future investigation. 
In summary, we provide the first evidence using a genetic model that loss of 
SERCA2 plays a pivotal role in the pathogenesis of diabetes, specifically leading to a 
cell autonomous defect in β cell secretory function, Ca2+ homeostasis, proliferation, and 
survival. Additional studies employing tissue specific mouse models of SERCA2 deletion 
are needed to unravel the relative contributions of SERCA2 loss in the β cell versus 
peripheral tissues. In the meantime, a growing body of evidence suggest that strategies 
to prevent loss of SERCA2 expression by exogenous overexpression (246) and/or 
modulation of SERCA2 activity via a small molecule approach represent viable 
strategies to improve glucose homeostasis (245). Finally, these data also have 
relevance for humans with Darier disease, in which one copy of the ATP2A2 gene is 
defective. Although metabolic effects of SERCA2 haploinsufficiency have not been 
reported in these individuals, a selective predisposition to diet-induced metabolic 
disease and other conditions, such as heart disease (281), could easily be overlooked in 
this rare population and should be further studied.   
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CHAPTER FOUR 
Summary and Perspective 
4.1 Summary 
DM is a disease of increasing prevalence that greatly influences quality of life. All 
three major types of diabetes (T1D, T2D and GDM) are the result of a relative deficiency 
in insulin secretion. Insulin is the only hormone that decreases blood glucose, which it 
does by activating the insulin receptor signaling pathway in peripheral tissues to induce 
glucose uptake by GLUT4 translocation. Insulin is secreted by a specialized endocrine 
cell type, the β cell, which resides in pancreatic islets. Similar to other endocrine cells, β 
cells possess specialized machinery to guarantee highly efficient hormone biosynthesis, 
storage and secretion in response to physiologic stimuli. These adaptations include a 
robust ER with high Ca2+ storage capacity, well packaged secretory granules and low 
basal proliferation rate. The most unique feature of β cells is the highly regulated 
orchestration between nutrient stimuli and insulin secretion, a process that occurs mainly 
through Ca2+ mobilization triggered by both metabolism and PKA-dependent pathways.  
Under normal conditions, efficient Ca2+ mobilization in the β cell leads to healthy 
Ca2+ oscillations that are synchronized with insulin secretion and nutrient metabolism. 
However, as environmental insults like GLT and pro-inflammatory cytokines challenge 
the β cells during the pre-diabetic state, β cells undergo a transition from a state of 
compensation, characterized by upregulation of UPR and cellular proliferation, to a state 
of decompensation, which includes terminal ER stress and apoptosis. During the 
development of T2D, insulin biosynthesis is greatly reduced in later stages of the 
disease, and the responsiveness to nutrient stimuli is blunted.  These impairments occur 
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concurrently with Ca2+ dyshomeostasis, manifested as a decrease in ER Ca2+ storage 
and sustained high levels of cytosolic Ca2+.  
Ca2+ homeostasis is maintained both by Ca2+ channels and Ca2+ pumps that 
control ion gradients between different cellular compartments. As one of the most 
important cellular Ca2+ pools, ER Ca2+ homeostasis is regulated primarily by the SERCA 
pump, which transports 2 Ca2+ ions into the ER lumen with each catalytic cycle. 
SERCA2 is the most abundant isoform expressed in the β cell, and it also has the 
highest affinity for Ca2+. Previous studies from our lab discovered that SERCA2 is greatly 
reduced in rodent and human diabetic β cells and in cultured β cells treated with 
conditions that simulate diabetic conditions. Through promoter analysis and in vitro and 
in vivo confirmation, we found that this decrease in SERCA2 expression during diabetes 
is partly due to down regulation of the transcription factors, PPAR-γ and Pdx-1. 
Overexpression/restoration of either of these factors was able to rescue the expression 
of SERCA2 at both the transcript and protein level.  
Previous studies have suggested that pro-inflammatory cytokines induce down-
regulation of SERCA2 through NO-dependent pathways. However, it was still unclear 
that in the context of inflammatory signaling, SERCA2 is regulated at transcriptional or 
translational levels. Thus, we first performed assessment of SERCA2 protein and mRNA 
stability in INS-1 cells, rat islets and human islets treated with pro-inflammatory 
cytokines combined with actinomycin D or cycloheximide to block global transcription or 
translation.  IL-1β treatment led to increased iNOS gene and protein expression that 
occurred concurrently with activation of AMPK.  IL-1β led to decreased SERCA2b mRNA 
and protein expression, while time-course experiments revealed a reduction in protein 
half-life with no change in mRNA stability.  Moreover, SERCA2b protein, but not mRNA, 
levels were rescued by treatment with the NOS inhibitor L-NMMA, whereas the NO 
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donor SNAP and the AMPK activator AICAR recapitulated the effects of IL-1β on 
SERC2b at post-translational level. Similarly, IL-1β-induced reductions in SERCA2b 
expression were rescued by pharmacological inhibition of AMPK with compound C or by 
transduction of a dominant negative form of AMPK, while β cell death was prevented in 
parallel.  Finally, to determine a functional relationship between NO, AMPK signaling and 
SERCA2b activity, Fura-2AM Ca2+ imaging experiments were performed in INS-1 cells.  
Consistent with observed changes in SERCA2b expression, IL-1β, SNAP, and AICAR 
increased cytosolic Ca2+ and decreased ER Ca2+ levels, suggesting congruent 
modulation of SERCA activity under these conditions.  In aggregate, the results in 
Chapter 2 show that SERCA2b protein stability is decreased under inflammatory 
conditions through NO and AMPK-dependent pathways, and provide novel insight into 
pathways leading to altered β cell calcium homeostasis and reduced β cell survival in 
diabetes.    
Next, to study the consequences of losing SERCA2 in β cells, we utilized a whole 
body SERCA2 heterozygous mouse model to analyze the in vivo function of SERCA2. 
To this end, SERCA2 heterozygous mice (S2HET) were challenged with HFD containing 
45% of kilocalories from fat.  After 16 weeks of HFD, S2HET mice were found to have 
lower serum insulin concentrations, higher blood glucose levels and significantly reduced 
glucose tolerance compared to wild-type controls. Adiposity and systemic and tissue-
specific insulin sensitivity were not different between S2HET mice and controls, 
suggesting an impairment in insulin secretion rather than a change in insulin action in 
the periphery. Consistent with this indication of β cell dysfuntion, S2HET islets and 
SERCA2-deficient INS-1 cells exhibited increased ER stress, altered insulin production 
and proinsulin processing, and reduced β cell mass and proliferation.  Furthermore, 
glucose stimulated insulin secretion and cytosolic Ca2+ oscillations were reduced in 
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HFD-fed S2HET islets. Notably, application of a small molecule activator of SERCA2 
was able to rescue the oscillatory defects in S2HET islets, and GSIS was also greatly 
improved in cadaveric human islets from both healthy donors and donors with T2D when 
treated with this activator. In aggregate, the data in Chapter 3 suggest a critical role for 
SERCA2 and the maintenance of ER Ca2+ stores during the in vivo β cell compensatory 
response to diet induced obesity.  
In summary, our data suggest that SERCA2 is a target of diabetic stresses in β 
cells at transcriptional and translational levels. This impairment in the function of 
SERCA2 leads to a loss of ER Ca2+ homeostasis, which plays an important role in the 
dysfunction and death of pancreatic β cells under diabetogenic conditions. Specifically, 
SERCA expression influences the adaptive compensatory response in β cells, including 
insulin biosynthesis, regulated insulin secretion and hyperplasia. Whereas the transition 
between compensation and decompensation during development of T2D is usually 
characterized by compromised β cell function, loss of SERCA function might be one of 
the key contributing factors in this transition point. Furthermore, correcting these defects 
by increasing SERCA2 function might have protective effects in β cells. Our data 
indicate that SERCA might be a therapeutic target with great potential in the treatment of 
diabetes. The small molecule activator of SERCA2 applied in this dissertation could be a 
promising candidate to clinically rescue ER stress-induced β cell apoptosis and improve 
insulin secretion during the progression of T2D.   
4.2 Limitations and future studies 
The work presented in this dissertation suggests an important role for SERCA2 in 
ER Ca2+ homeostasis in β cell function and survival. However, there are still a number of 
topics and areas that we did not have time to fully elucidate. To promote SERCA2 as a 
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potential therapeutic target, there are multiple important aspects that need further 
analysis.  
4.2.1 Post-translational regulation of SERCA2 under diabetic stresses  
a. Degradation of SERCA2 
The first half of our study provided a preliminary discovery of SERCA2 post-
translational regulation in pancreatic β cells in normal and diabetic conditions. These 
mechanisms include NO- and AMPK-dependent down-regulation of protein stability and 
enzyme activity induced by pro-inflammatory cytokines and a pharmacological small 
molecule activator of AMPK. However, the specific degradation mechanisms relevant to 
SERCA2 stability in β cells are still unclear. While we were the first group to address 
SERCA2 protein stability and activity in physiological conditions in β cells, the role of 
SERCA has been studied in other tissues or cell types. For example, in cardiomyocytes, 
ischemia-reperfusion-induced calpain activation resulted in SERCA2a degradation 
through ER associated degradation which was mediated by the proteasome (326). 
Meanwhile, a mass spectrometry study showed that irreversible oxidation on cysteine-
674 of SERCA2a was associated with its degradation. The end product of this oxidation 
reaction is a 60-70 kD protein segment (327).  These findings suggest that diabetogenic 
stress may result in the loss of full length SERCA protein.  
The protein degradation mechanisms in cell mainly include proteasome-
dependent and lysosome-dependent. To elucidate the degradation mechanisms of 
SERCA2 in β cells, the classic methods is treating cultured β cell lines or isolated islets 
with small molecule inhibitors of degradation machinery, such as proteasome inhibitors 
(MG132) and lysosome inhibitors chloroquine (328). However, considering SERCA2 is a 
relatively stable protein with a half-life of about 24 h, chronic treatment with these 
93 
inhibitors might generate cytotoxicity. Alternatively, we could transduce cells with 
adenovirus encoding kinase dead enzymes or targeted knockdown by RNAi to block the 
endogenous degradation pathways. Then, we could elucidate how SERCA2 is degraded 
in β cells and how it might be influenced in the diabetic models we used in this 
dissertation. Notably, we have observed a smaller second protein band around 60-70 kD 
that could be detected by the SERCA2 antibodies reactive to the segment, which is 
consistent with the study in cardiomyocytes. Furthermore, this band accumulates under 
stress conditions, suggesting a specific modification-dependent degradation.  Finally, 
using unbiased approaches, we could perform mass spectrometry to unravel different 
sites of post-translational modifications of SERCA2 in β cells. Despite previous studies 
proposing several phosphorylation, glycosylation and glutathione sites on SERCA2a, 
none of these modifications have been confirmed for SERCA2b in β cells. 
b. SERCA2 binding proteins 
Previous studies focusing on SERCA interacting proteins have been mostly 
performed in muscle cells or human embryonic kidney cell lines (HEK 293), or on 
isolated proteins produced in E. coli. These isolated proteins usually bind to SERCA2 to 
inhibit its activity, including Bcl-2 (329), S100a (330), short peptide encoded by small 
open reading frames (331), presenilin (332), phospholamban or sarcolipin (333). 
Interestingly, SERCA2 monomers also appear to interact with each other to form dimers 
in HEK 293 cells.  This dimer was shown to be important in regulating SERCA2 function 
in this cell type (334). Thus, the down-regulation of SERCA2 expression might work as a 
feedforward mechanism to inhibit its own activity.  However, considering the differences 
in β cells, especially given the fact that the most well-studied phospholamban and 
sarcolipin are not expressed in β cells, indeed more experiments are required to explore 
the interacting proteins of SERCA2 in β cells.  
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These unanswered questions highlight the importance of prioritizing 
immunoprecipitation of SERCA2 and followed by mass spectrometry and interactome 
analysis. Furthermore, this could help elucidate pathways that regulate SERCA2 activity 
under different diabetogenic stressors by performing these experiments following 
treatments with GLT, pro-inflammatory cytokines and ER stress inducers. To increase 
the abundance and pull down efficiency of SERCA with immunoprecipitation, we could 
overexpress tagged SERCA2 in β cells.  This approach, however, could be limited by 
potential problems associated with overexpression.  
4.2.2 SERCA2 in regulating β cell proliferation 
The second half of the study in this dissertation focused on the in vivo effects of 
SERCA2 in regulating whole body glucose homeostasis. Our data suggest that β cells 
are heavily dependent upon SERCA2 during the compensatory response to diet induced 
obesity. The defects associated with SERCA2 haploinsufficiency involved decreased β 
cell mass with lower proliferation rates, higher susceptibility to ER stress induced cell 
death, impaired insulin processing and decreased regulated Ca2+ oscillation in response 
to glucose.  
Ca2+ mobilization was found to be the pacemaker of the cell cycle as early as 
1990 (228). The ER Ca2+ depot also plays a key role in many additional Ca2+-mediated 
signalling pathways. A number of studies have shown that increased cytosolic Ca2+ 
emanating from the ER is required for cell cycle initiation and cell proliferation (228, 323). 
SERCA2 has previously been found to be related to cell cycle and proliferation. In 
prostate cancer cells, epidermal growth factor (EGF)-, insulin-like growth factor (IGF)- 
and TNF-α-induced cell mitosis were all SERCA dependent (335, 336). Meanwhile, it 
was also observed that SERCA2 gene mutation in humans or haploinsufficiency in mice 
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results in a higher susceptibility to colon cancer, lung cancer and squamous cell 
carcinomas of oral mucosa, esophagus, and forestomach and papillomas in keratinized 
epithelial cells (337-340). These seemingly contrasting observations might due to cell 
type specificity, which might be further related to isoform expression profiles during 
proliferation and apoptosis. Indeed, smooth muscle cells express both SERCA2a and 
SERCA2b isoforms, and it was observed that an isoform expression pattern shift occurs 
in parallel with cell proliferation status. i.e., SERCA2b expression was more dominant 
during proliferative stages (341). Nevertheless, an efficient ER Ca2+ buffering system is 
crucial for the maintenance of the balance between mitosis and cellular function in many 
cell types (342, 343).   
In the current study, we did not elucidate the specific mechanisms by which 
SERCA2 directly or indirectly regulates the cell cycle. However, in the SERCA2 
knockout β cell line (S2KO) that we generated, we performed some preliminary studies 
and were able to see a correlation between lower cyclin D2 expression and decreased 
G1-S phase transition (Figure 27). To further pursue the hypothesis that SERCA2 
directly regulates cyclin D2, in vivo and in vitro models could be utilized. First of all, we 
could confirm the causation between SERCA2 deficiency and cyclin D2 deficiency by 
measuring the cyclin D2 expression levels in our S2HET mouse model. Secondly, we 
could also overexpress cyclin D2 in cultured SERCA2 knockout β cells to determine 
whether the decreased cell cycle progression is indeed cyclin D2-dependent.  
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Figure 27 SERCA2 deficiency in cultured β cells induced lower proliferation with 
cyclin D2 involvement.  
A. Thymidine incorporation experiments were performed in WT and S2KO INS-1 cells 
after 24h of seeding.  B-D. Protein and RNA were isolated from WT and S2KO INS-1 
cells, and qRT-PCR was used to measure, and analysis revealed decreased expression 
of cyclin D2 in S2KO cells. Reverse-transcribed RNA was subjected to qRT-PCR to 
measure genes involved in cell cycle regulation transcript levels (normalized to Actb) (A, 
C); Immunoblot analysis performed using antibodies against cyclin D1, cyclin D2, cyclin 
D3, cdk6, p15 and actin (B).; Quantitative protein levels of cyclin D2 are shown 
graphically (C); WT and S2KO cells were transduced with a SERCA2b expressing 
adenovirus or a LacZ control adenovirus. E, qRT-PCR was performed to measure cyclin 
D2 transcript levels. And F, Propidium iodide (PI) staining was performed.  Results are 
displayed as the mean ± S.E.M. n = 3/group. *p<0.05 **p<0.01 ***p<0.001  
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There are several other Ca2+ dependent molecules that might also be involved in 
SERCA2-mediated proliferative events (323). For example, a long-lasting increase in 
cytosolic Ca2+ (at least 1–2 h) is required for activation of the transcription factor, nuclear 
factor of activated T-cells (NFAT), which is activated by calcineurin and serves as the 
mediator of proliferation in almost all cell types. Depleted ER Ca2+ storage might 
contribute to blunted NFAT activation. Specifically, NFATc1 and NFATc3 might be 
closely involved since they were found to regulate cyclin D1 and D2 expression (344).  
Meanwhile, NFATc1 was also found to directly regulate IRS-2 expression in islets (345). 
Thus the study of SERCA’s relationship with NFAT might worth further study.  
Another possible link between SERCA and regulation of cell proliferation is 
Notch1, one of the receptors in the Notch signaling pathway that is important for cell-cell 
communication to control multiple cell differentiation processes during embryonic and 
adult life. In a recent study utilizing cell-based high-throughput screens in T cell acute 
lymphoblastic leukemia, SERCA inhibition was found to rescue abnormal Notch1 
signaling due to its leukemia associated mutations. Interestingly, this might also be due 
to a direct interaction between SERCA, Notch1 and presenilin (346).   
In addition to diet induced obesity models, another physiologic stimuli known to 
induce β cell hyperplasia is pregnancy (347). In mice, previous work has shown that 
there is an approximate 1.5 to 4-fold increase in maternal β cell mass during gestation, 
while failure in β cell mass expansion contributes to GDM. The increase in β cell mass 
during pregnancy was found to be mainly regulated by placental lactogen and prolactin 
mediated signaling pathways (348, 349). These types of molecules bind to prolactin 
receptors and activate downstream cascades of AKT, ERK, signal transducer and 
activator of transcription (STAT5) and Forkhead box protein M1 (FoxM1) (350). To study 
how SERCA2 deficiency may play a role in maintaining β cell function and proliferation 
during pregnancy, we could set up a gestational model using wildtype and S2HET 
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female mice. I would hypothesize that S2HET female mice would develop worsened 
glucose tolerance during late gestational stages due to lower β cell mass. Important 
analyses would include determination of whole body glucose homeostasis, β cell mass 
and adaptive hypersecretion. Early studies also applied pancreatic duct ligation as a 
model to induce β cell proliferation and regeneration. However, recent studies report that 
this model induces several irregular signals found to cause massive injury in pancreas 
(351, 352). These observations suggest that pancreatic duct ligation might not be an 
ideal model for β cell compensatory hyperplasia under physiological conditions of insulin 
resistance. 
4.2.3 β cell specific SERCA2 knock out mouse model 
Studies in this dissertation demonstrate that S2HET mice fed HFD had defects in 
β cells without a change in peripheral insulin resistance, suggesting that SERCA2 
deficiency is mostly influencing β cells. However, to further prove this, it is necessary to 
test the effect of a  β cell specific knockout mouse model. 
During the early stages of the current study, we developed a β cell specific 
SERCA2 knockout mouse model by crossing mice with a floxed SERCA2 gene with the 
Mip-CreERT line (conditional knockout created by tamoxifen administration). The β cell 
specific knockout animal is termed as MipCre-SERCA2 flox and SERCA2 flox mice 
would be used as littermate controls.  Interestingly, we noticed the that MipCre-SERCA2 
flox control mice demonstrated a better glucose tolerance compared to the SERCA2 flox, 
even before tamoxifen administration. Indeed, this protective effect was recently 
reported in several studies and has been shown to result from the presence of the 
human growth hormone (GH) emanating from GH mini gene insert on the Cre transgene.  
Thus, this background is not an ideal model to test the effects of SERCA2 loss (353-355).  
Recently, another β cell specific Cre mouse line, Ins1CreERT2, was developed, 
which has shown more equivalent metabolic features compared to non-Cre controls. 
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This line was generated by inserting the CreERT2 recombinase gene in the second exon 
of the Ins1 gene so that the coding region of the recombinase starts at the initiation 
codon and replaces the Ins1 coding sequence (356). Currently, we are crossing the 
Ins1CreERT2 to SERCA2 flox mice to generate the knockout colonies. We plan to start by 
confirming there is no overt protective effect of this Ins1CreERT2 background, and testing 
the knock out efficiency and specificity of SERCA2 in β cells. Next, whole body glucose 
tolerance and insulin tolerance tests will be performed to determine the β cell specific 
role of SERCA2.  
4.2.4 SERCA2 as a potential therapeutic target 
A well-organized report was published recently, which collectively summarized 
the research on β cell dysfunction in T2D from different fields, limitations of these studies 
and future directions. This paper pointed out several critical directions, including but not 
limited to: identification and characterization of genetic loci for T2D; pathways that 
improve β cell function and mass; identification of circulating factors and details of the 
metabolic environment arising from the communication of other organs and the β cells in 
regulating their function and health (357).  
The studies in this dissertation have demonstrated that β cell health and function 
rely heavily upon correct Ca2+ homeostasis. SERCA2 is critical for proper control of ER 
Ca2+ balance and is therefore a potential therapeutic target in other tissues including 
liver and cardiac muscle (245, 358). We now propose that activating SERCA2 in β cells 
may also protect against diabetes progression.  Indeed, in the last part of our studies, we 
observed exciting effects of a SERCA2 small molecule activator, as this compound was 
able to rescue tunicamycin induced cell death, increase ER Ca2+ storage, and improve 
glucose stimulated Ca2+ oscillations and insulin secretion (Figure 26 and 28). 
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Figure 28. Small molecule of SERCA2 activator improves glucose stimulated 
insulin secretion without alterating insulin content 
Human islets from healthy cadaveric donor were treated with 10 µM of CDN for 2 h or 24 
h with or without a cytokine mix of IL-1β and TNF-α. Islets from cadaveric donor of T2D 
were treated with 10 µM of CDN for 2 h. A. Glucose stimulated insulin secretion (GSIS) 
was measured and normalized to total insulin content. B. Relative insulin content was 
measured after treatment and GSIS normalized to DNA content. Results are displayed 
as the mean ± S.E.M; n = at least 3 samples per group.  Indicated comparisons are 
significantly different; *, p<0.05 compared to healthy group; **, p<0.01 compared to 
healthy group. #, p<0.05 compared to cytokine-treated alone group or T2D group.  
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All in all, the discoveries in this dissertation have improved our understanding of 
the importance of ER Ca2+ homeostasis in pancreatic β cells.  SERCA2 was found to be 
down regulated under diabetic conditions and was identified to play a critical role in the 
compensatory response of the β cell to diet induced obesity. Overexpression of SERCA2 
or small molecule SERCA2 activator were able to improve ER Ca2+ storage, Ca2+ 
mobilization and insulin secretory profiles, suggesting that SERCA2 could be a 
promising potential therapeutic target for the prevention of diabetes.  
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CHAPTER FIVE 
Materials and Methods 
5.1 Materials 
5.1.1. Animals, islets isolation and human islets preparation 
a. Mice 
C57BL/6J (WT) mice were obtained from Jackson Laboratories (Bar Harbor, ME) 
at 12 weeks of age. SERCA2 heterozygous (S2HET) mice were developed by Gary E. 
Shull of the University of Cincinnati, backcrossed onto a C57BL6/J background for at 
least 10 generations, and maintained under protocols approved by the Indiana University 
Institutional Animal Care and Use Committee, the U.S. Department of Agriculture’s 
Animal Welfare Act (9 CFR Parts 1, 2, and 3), and the Guide for the Care and Use of 
Laboratory Animals  
b. Rats  
Male Wistar rats (250–300 g) were purchased from Harlan Lab in Indianapolis, IN, 
USA, and maintained under protocols approved by Indiana University Institutional 
Animal Care and Use Committee.  
c. Human islets  
Human cadaveric islets isolated from non-diabetic donors were obtained from the 
Integrated Islet Distribution Program or the National Disease Research Interchange.  
Upon receipt, human islets were hand-picked and allowed to recover overnight in 
Dulbecco’s modified essential medium (DMEM) medium containing 5.5mM glucose, 10% 
fetal bovine serum (FBS), 100U/ml penicillin, and 100μg/ml streptomycin. 
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5.1.2 Cell culture, islets isolation and culture 
INS-1 832/13 rat insulinoma cells were cultured in regular 11mM glucose Roswell 
Park Memorial Institute medium (RPMI) 1640 supplemented with 10mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, 1mM sodium pyruvate, 
50μM β-macaptoethanol and, 10% FBS, penicillin and streptomycin.  
C57BL6/J WT, S2HET mice or rat pancreatic islets were isolated by collagenase 
digestion as described previously (359). The islets were hand-picked, and allowed to 
recover overnight in regular RPMI supplemented with 10% FBS, 100U/ml penicillin, and 
100μg/ml streptomycin. 
5.1.3. Primers, antibodies and reagents 
Standard polymerase chain reaction (PCR) reactions for genotyping (Table 1) 
and quantitative reverse transcription-PCR (qRT-PCR) for gene expressions were 
performed using oligonucleotides synthesized by Invitrogen (Table 2).  
Antibodies used in western blotting, immunofluorescent and 
immunohistochemistry staining are listed in Table 3. 
Chemicals and reagents used in this dissertation are listed in Table 4  
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Table 1 Genotyping Primers 
Gene Orientation Sequence 
ATP2A2 
(SERCA2) 
Forward (5’-3’) CGGCCTTCTAGAATTGCCGGCTG 
Reverse (5’-3’) CTTACGAAAGATATACATGCTGCCAGCAG (for wildtype) 
Reverse (5’-3’) GCATGCTCCAGACTCCCTTG  (for ATP2A2+/-) 
Mip-CreERT 
Forward (5’-3’) GCGGTCTGGCAGTAAAAACTATC 
Reverse (5’-3’) GTGAAACAGCATTGCTGTCACTT 
SERCA2flox/flox 
Forward (5’-3’) TCTTCATAACACACGCCAATTT 
Reverse (5’-3’) CCCTTTGCTGCCAATTAACTATT 
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Table 2 Quantitative RT-PCR Primers 
Gene Species Forward (5’-3’) Reverse (5’-3’) 
SERCA2b Rattus rattus GTGGAACCTTTGCCACTCAT TGTGCTGTAGACCCAGACCA 
SERCA3 Rattus rattus TGTCTCTGCCTGTCATCCTG CTAGAAATGGCCGGTGTTGT 
RyR2 Rattus rattus ACGGCGACCATCCACAAAG AAAGTCTGTTGCCAAATCCTTCT 
IP3R3 Rattus rattus TGACCTGGGCAGCCAGCC GTCTCCAAGGTCTGGATGAC 
DNAjc3 Rattus rattus TCCCGAATCTGCTGATCGTT GGACTATGAAGCTGCCCAGG 
Pdia4 Rattus rattus GAGTCGGTGACCCAGGCTAC TTTCCCCAGGGAGACTTTCA 
Hsp90b1 Rattus rattus ACACCACAGAAGACACCACAGATG GGGAGAGGGAGGCTTGGG 
Grp78 Rattus rattus CCACCAGGATGCAGACATTG AGGGCCTCCACTTCCATAGA 
Total Xbp-1 Rattus rattus AGCACTCAGACTACGTGCGCCTC CCAGAATGCCCAAAAGGATATCAG 
Spliced Xbp-1 Rattus rattus CTGAGTCCGCAGCAGGT TGTCAGAGTCCATGGGAAGA 
SERCA2b Mus musculus GATCCTCTACGTGGAACCTTTG CCACAGGGAGCAGGAAGAT 
SERCA3 Mus musculus AGGGGAAGCTAAGAAGCCAG CCCTCAGACTCCTCCTACCC 
DNAjc3 Mus musculus GACAGCTAGCCGACGCCTTA GTCACCATCAACTGCAGCGT 
Pdia4 Mus musculus TGACCCGGCCTACTTGCA GTGTGGTGAAACTTGTAATCTTCTCTCA 
Hsp90b1 Mus musculus TGTATGTACGCCGCGTATTCA TCGGAATCCACAACACCTTTG 
Grp78 Mus musculus TTCAGCCAATTATCAGCAAACTCT TTTTCTGATGTATCCTCTTCACCAGT 
Total Xbp-1 Mus musculus TGGCCGGGTCTGCTGAGTCCG GTCCATGGGAAGATGTTCTGG 
Spliced Xbp-1 Mus musculus CTGAGTCCGAATCAGGTGCAG GTCCATGGGAAGATGTTCTGG 
Pcsk1 Mus musculus Rattus rattus 
CCTCCTACAGCAGTGGTGATTACA 
GGGTCTCTGTGCAGTCATTGT 
Ins1 Mus musculus Rattus rattus 
AGCAAGCAGGTCATTGTTCC 
GACGGGACTTGGGTGTGTAG 
Ins2 Mus musculus Rattus rattus 
TCTTCTACACACCCATGTCCC 
GGTGCAGCACTGATCCAC 
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Table 3 Antibodies for Western Blotting and Immuno-staining 
Targeted protein Host Species Manufacturer Dilution 
Western blotting 
Actin Mouse MP bioscience 1:10000 
AKT Mouse Cell Signaling 1:1000 
Inducible Nitric Oxidesynthase (iNOS) Rabbit Millipore 1:1000 
IκBα Rabbit Santa Cruz 1:1000 
Phospho-AKT (Th473) Rabbit Cell Signaling 1:1000 
PC1/3 Rabbit Cell Signaling 1:500 
Phospho-Acetyl-CoAcarboxylase (ACC) Rabbit Cell Signalling 1:1000 
Phospho-AMPKα (Th172) Rabbit Cell Signalling 1:1000 
SERCA2 Goat Santa Cruz 1:1000 
SERCA3 Rabbit Sigma-Aldrich 1:1000 
Total-ACC Rabbit Cell Signalling 1:1000 
Total AMPKα rabbit  Rabbit Cell Signalling 1:1000 
Total caspase 3  Rabbit Cell Signalling 1:1000 
Mouse IgG (IRDye 800CW) Donkey Li-cor 1:10000 
Goat IgG (IRDye 800CW) Donkey Li-cor 1:10000 
Rabbit IgG(IRDye 680RD) Donkey Li-cor 1:10000 
Immune-staining 
Glucagon Rabbit Santa Cruz 1:500 
Insulin Guinea pig Invitrogen 1:250 
Insulin Rabbit Santa Cruz 1:250 
PCNA Rabbit Santa Cruz 1:100 
Rabbit IgG 488 Goat Molecular probe 1:5000 
Guinea pig IgG 555 Goat Molecular probe 1:5000 
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Table 4 Chemicals, and Reagents 
Name Manufacturer 
Cycloheximide Sigma-Aldrich 
Actinomycin D Sigma-Aldrich 
Compound C Sigma-Aldrich 
5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) TRC 
Recobinant mouse and human interleukin-1 β (IL-1β) Life Technology 
Tumor necrosis factor α (TNF-α) Life Technology 
Interferon γ (IFN-γ) Life Technology 
Caffeine Santa Cruz  
NG-monomethyl L-arginine (L-NMMA) Santa Cruz  
Carboxy-PTIO potassium salt (C-PTIO) Cayman Chemical 
S-nitroso-N-acetyl-D,L-penicillamine (SNAP) Cayman Chemical 
D-Glucose Sigma-Aldrich 
Palmitic acid Sigma-Aldrich 
Hanks' Balanced Salt Solution (HBSS) Lonza 
Carbachol Millipore 
Recombinant human insulin 
Novo Nordisk 
Pharmaceutical 
Industres Inc. 
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5.2 Methods 
5.2.1 Animal study 
Male mice with heterozygous deficiency of SERCA2 and wild-type littermate 
controls were fed high fat diet containing 45% of kilocalories from fat (Harlan Laboratory, 
Indianapolis, IN) beginning at 8 weeks of age. Intraperitoneal glucose tolerance tests 
(IPGTT) and oral glucose tolerance tests (OGTT) were performed after 6 h of fasting and 
administration of glucose at a dose of 2 g/kg total body weight.  Glucose was 
intraperitoneal injected or gavaged by 20 GA gavaging needle (Kent Scientific Corp, 
Torrington, CT) followed by fasting blood glucose measurements. Insulin tolerance tests 
(ITT) were performed after a 5-6 h fast and intraperitoneal administration of regular 
human insulin at a dose of 0.75 IU/kg total body weight. All blood samples were 
collected from the tail vein and glucose levels were determined using AlphaTRAK 
glucometer (Abbott Laboratories, Abbott Park, IL). 
At 25 weeks of age, in vivo glucose stimulated insulin secretion (GSIS) assays 
described in section 5.2.4 were performed, and blood samples were collected at 
baseline and then 10 min after intraperitoneal glucose injection (2 g/kg body weight).  
Serum insulin levels were measured by enzyme-linked immunosorbent assay (ELISA) 
(Crystal Chemical, Chicago, IL).   
Plasma was obtained at 6 h fasting time point and fed time point (at termination 
point in the morning between 9-10am) for insulin, proinsulin and c-peptide content 
measurement. The blood was collected by EDTA coated collection tubes through tail 
vein for fasting and heart puncture for terminal points. After centrifugation and collection 
of the supernatant as the plasma sample, the insulin content was measured by a mouse 
insulin, proinsulin and c-peptide ELISA kit (ALPCO Diagnostics, Salem, NH).  
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Serum insulin and proinsulin levels were measured using ELISAs from Crystal 
Chemical (Chicago, IL) and ALPCO Diagnostics (Salem, NH), respectively. Dual X-ray 
Absorptiometry (DEXA) analysis was performed to estimate body composition using the 
Lunar PIXImus II (GE Medical Systems) mouse DEXA.   
At treatment end and euthanasia, pancreata were rapidly dissected, weighed, 
fixed, embedded in paraffin, and sectioned longitudinally at 100-micron intervals. β cell 
mass and proliferation were assessed, as detailed in previous publications (181), using 
antibodies outlined in Supplemental Table 1. Isolated islets were fixed in 2% 
glutaraldehyde and 4% paraformaldehyde in 0.1 M sodium cacodylate buffer and 
transferred to the Advanced Electron Microscopy Facility at the University of Chicago 
(Chicago, IL) to generate transmission electron micrographic images. The relative 
percentages of mature, immature and rod-like secretory granules were quantitated 
manually as outlined previously and using ImageJ software (311) . 
To assess insulin signaling, mice were fasted for 6 h and injected 
intraperitoneally with insulin (10 IU/kg) or saline. After 10 min, liver, epididymal adipose, 
and gastrocnemius skeletal muscle were harvested. Tissues were sonicated in 2% SDS 
lysis buffer and immunoblotting was performed to measure AKT phosphorylation at 
serine 473.   
5.2.2 Immunofluorescence and immunohistochemistry staining  
Pancreata from at least five mice per treatment group were weighted, fixed by Z-
fix (ANATECH LTD, Battle Creek, MI) overnight, paraffin embedded, and sectioned 
longitudinally at 100 microns intervals. Immunohistochemical analysis were applied to 
assess β cell mass using rabbit anti-insulin antibody, A Zeiss Axio Observer Z1 inverted 
microscope equipped with an Orca ER CCD camera (Hamamatsu Photonics, 
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Hamamatsu City, Japan) was used to acquire digital images of the entire stained 
longitudinal pancreatic section.  
Immunofluorescent imaging using was applied to evaluate β cell proliferation and 
α cell composition. Antibodies used in these experiments are listed in Table 3. 
5.2.3 Cell culture, islets culture and in vitro treatment 
INS-1 832/13 rat insulinoma cells and islets isolated from C57BL6/J WT, S2HET 
mice or rat were used as in vitro or ex vivo model.  
To measure the ER Ca2+ content in individual β cell from isolated mouse islets, 
Accutase (Innovative Cell Technologies, Inc. San Diego, CA) was used to disperse intact 
islets. In brief, 500µl of Accutase was added to ~100 islets pre-washed with PBS. After 
incubation at 37C for 20min with gentle pipetting occasionally, 105 of cells were seeded 
in a two-chamber imaging dish pre-treated with Poly-L-Lysine (Sigma-Aldrich, St. Louis, 
MO).  
A CRISPR/Cas 9 based technique was utilized to produce a SERCA2 knockout 
(S2KO) INS-1 832/13 cell line in the Genome Engineering Center at Washington 
University (St. Louis, MO). 
For half-life study, time-course experiments were performed to determine the 
half-life of SERCA2b protein or mRNA using 10μM cycloheximide or 1μg/ml actinomycin 
D, respectively. 
5.2.4 GSIS in INS-1 cells and isolated islets 
GSIS assays were performed in INS-1 cells and isolated mouse islets or human 
islets from cadaveric donor. In brief, fully confluent INS-1 cells were pre-incubated in 
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secretion buffer (SAB, including 14 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.16 mM 
MgSO4, 2.5 mM CaCl2 in 0.2M HEPES buffer, pH7.2) with 2.5mM glucose for 1 h 
followed by another 2 h of either 2.5mM or 16.7 mM glucose SAB. For groups of islets, 
the incubation was 1) pre-incubation in 2.5mM glucose SAB for 1 h; 2) 2.5mM glucose 
SAB for 2 h and collect the supernatant; 3) 16.7 mM glucose SAB for 2 h and collect the 
supernatant. After the series of incubation, cells or islets were lysed in 10% NP40 lysis 
buffer. Insulin content in the SAB collected or cell lysate were determined by human 
insulin-specific radioimmunoassay/RIA (HI-14K, Millipore. Billerica, MA), and data were 
expressed relative to total cell protein concentration for INS-1 cells or total DNA content 
for islets. The protein concentration was determined using Bio-Rad DC protein assay 
(Bio-Rad, Hercules, CA) and the DNA content was determined using Quant-iT 
PicoGreen dsDNA Assay Kit (Thermo Fisher Scientific, Florence, KY) 
5.2.5 Stress simulation 
To simulate the inflammatory milieu of diabetes, cells and rat islets were treated 
in RPMI media containing 5 ng/mL of mouse IL-1β for indicated times. For human islet 
studies, DMEM media containing 5 ng/mL of mouse or human IL-1β, 10 ng/mL TNF-α, 
and 100 ng/mL IFN-γ was used.  
To mimic the glucolipotoxicity in diabetic milieu, INS-1 cells or mouse islets were 
cultured in RPMI containing 25 mM glucose and 500 µM Bovine serum albumin (BSA)-
conjugated palmitate for 24 h. 
5.2.6 Viability assay and nitrite assay 
A CellTiter-Glo Luminescent Cell Viability Assay (Promega; Madison, WI, USA) 
was used according to the manufacturer’s instructions. 
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Nitric oxide (NO) generation was measured using cultured media after cytokine 
treatment using the Promega Griess Reagent System. (Promega; Madison, WI, USA) 
5.2.7 Adenovirus treatment 
A dominant-negative AMPK (AMPK DN) recombinant adenovirus expressing an 
HA-tagged human α1 subunit with a D159A mutation in the ATP binding domain was 
purchased from Eton Biosciences (San Diego, CA, USA). An adenovirus encoding firefly 
luciferase under control of the cytomegalovirus promoter was used as a control. For loss 
of function studies, INS-1 832/13 cells were transduced with 107 pfu/ml of control of 
AMPK DN adenovirus when cells reached 60-70% confluency.  Rat, mouse, or human 
islets were transduced on the day of isolation or receipt using 5*107 pfu/ml of control or 
AMPK DN adenovirus. For SERCA2b rescue studies, S2KO and WT INS-1 cells were 
transduced with an adenovirus expressing SERCA2b or LacZ with 107 pfu/ml. After 
overnight incubation, the culture media was replaced with fresh media followed by an 
additional 24-32 h of culture.   
5.2.8 Cell cycle analysis by [3H]-thymidine incorporation assay and Propidium 
Iodide (PI) staining 
INS-1 cells proliferation was assessed by measuring the incorporation of [3H]-
thymidine into genomic DNA. [3H]-thymidine was added to INS-1 cells cultured in 12-
well 24h after seeding at a final concentration of 1 μCi/ml medium. After 2 h, the DNA 
was precipitated in 500 μl of cold 10% tricholoroacetic acid and solubilized by the 
addition of 80 μl of 0.3 N NaOH. The amount of [3H]-thymidine incorporated into DNA 
was measured by liquid scintillation counting (PerkinElmer, Waltham, MA) and 
normalized by total cellular protein. 
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For PI staining, at the end of the treatment, INS-1 cells were digested by trypsin, 
collected and resuspended in PBS. After being fixed by adding 100% ethanol (final 
percentage at ∼66%) and incubated for 15 min on ice, the cells were then washed with 
PBS and incubated in PI solution containing 50 μg/ml PI. After being incubated for 40 
min at 37°C, the imaging cytometry analysis was performed in CellometerTM K2 
(Nexcelom Bioscience, Lawrence, MA) 
5.2.9 Total RNA isolation and quantitative real-time PCR (qRT-PCR) 
Cultured cells or isolated islets were processed for total RNA isolation using 
RNeasy Mini plus or Micro plus kits (Qiagen, Valencia, CA), according to manufacturer’s 
instructions For reverse transcription-PCR experiments, total RNA was processed using 
Moloney murine leukemia virus (MMLV) reverse transcriptase (Invitrogen, Grand Island, 
NY). Subsequently, qRT-PCR was performed using JumpStart™ Taq DNA Polymerase 
(Sigma-Aldrich, St. Louis, MO), SYBR Green I dye and primers listed in Table 2.  
5.2.10 Immunoblot analysis 
Cells were lysed in 1% IGEPAL reagent supplemented with 10% glycerol, 16 mM 
NaCl, 25 mM HEPES, Sigma-Aldrich, St. Louis, MO), 60 mM n-octylglucoside (Research 
Products International Corp.), phosphatase inhibitor cocktails (PhosSTOP tablets, Roche) 
and phosphatase inhibitor cocktails (EDTA-free cOmplete tablets, Roche). Protein 
concentration was measured using the Bio-Rad DC protein assay (Bio-Rad, Hercules, 
CA) and a SpectraMax M5 multiwell plate reader (Molecular Devices, Sunnyvale, CA). 
Equal concentrations of proteins were suspended in 10% SDS solution and heated to 
70C for 5 minutes. Protein lysates were electrophoresed and transferred to methanol-
activated PVDF membrane (Immobilon-FL Transfer Membrane from Millipore). 
Membranes were then blocked with Odyssey blocking buffer (LI-COR, Lincoln, NE) prior 
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to incubation with primary antibodies listed in Table 3. Subsequently, membranes were 
incubated with IRDye 800 or 680 fluorophore-labeled secondary antibodies from LI-COR. 
Protein bands were visualized using the Odyssey System (LI-COR, Lincoln, NE) and 
quantified with Image J software (NIH). The phosphorylated protein levels presented in 
bar graphs were normalized by total protein levels, and the total (e.g., non-
phosphorylated or un-cleaved form) protein levels were normalized to actin protein levels. 
5.2.11 Cytoplasmic calcium (Ca2+) imaging 
Intracellular cytosolic Ca2+ was measured using the ratiometric Ca2+ indicator 
Fura-2-acetoxymethylester (Fura-2 AM) from Life Technologies. In brief, INS-1 832/13 
cells were seeded in glass bottom 50 mm plates for 48 h and then treated as indicated. 
Prior to imaging, INS-1 cells were incubated at 37ºC and 5% CO2 in 4 μM Fura-2 AM 
and 0.02% pluronic F127 (Life Technologies) for 1 h, and then washed and incubated 
with Hank’s Balanced Salt Solution (HBSS, Life Technologies) supplemented with 0.1% 
BSA and 2.5mM CaCl2. A small-volume chamber from Warner Instruments was mounted 
on the microscope stage; INS-1 cells were perfused with a gradient pump (Bio-Rad) and 
maintained at 37°C and 5% CO2.  To activate ryanodine receptors and reversibly empty 
ER Ca2+ stores, 10 mM caffeine in basal HBSS was employed. Fura-2 AM fluorescence 
was measured with excitation at 340 nm and 380 nm and emission at 510 nm, and 
images were captured using a Zeiss Z1 microscope with a 10x objective. Results were 
analyzed with Zen Blue software (Zeiss). 
To measure intracellular Ca2+ mobilization, the FLIPR Calcium 6 Assay Kit 
(Molecular Devices) was used according to the manufacturer’s instructions. In brief, INS-
1 832/13 cells were plated at a density of 5000 cells/well in black wall /clear bottom 96 
multi-well plates (Costar, Tewksbury, MA) and cultured for 2 days prior to treatment. 
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After ~22 h of treatment, Calcium 6 reagent was directly added to cells and incubated for 
an additional 2 h at 37 °C and 5% CO2. Data acquisition on the FlexStation 3 system 
(Molecular Devices) was acquired at room temperature using a 1.52-sec reading interval 
throughout the experiments. To empty ER Ca2+ stores, caffeine dissolved in HBSS was 
injected into each well to achieve a final concentration of 10 mM and fluorescence was 
recorded for an additional 120 sec. The increase of intracellular Ca2+ was determined as 
the increase in Calcium 6 dye fluorescence. The ratio of Max-Min Ca2+ levels over basal 
Ca2+ levels were calculated as an indirect estimation of ER Ca2+ storage. In Ca2+ free 
situations, after 2h incubation with Calcium 6 reagent, media was substituted with HBSS 
without Ca2+ prior to data acquisition. 
5.2.12 Fluorescence Lifetime Imaging Microscopy (FLIM) for ER Ca2+ imaging 
A D4ER adenovirus described previously was used for direct analysis of ER Ca2+ 
levels (256). Briefly, INS-1 cells or dispersed islets cells were cultured for 18 h with the 
D4ER adenovirus. Cells were then allowed to recover for 24 h. FLIM was carried out in 
accordance with a protocol published previously. In brief, the Alba Fast FLIM system 
(ISS Inc., Champaign, IL) was coupled to an Olympus IX71 microscope using a 60 
water-immersion lens (Olympus, Tokyo, Japan). Confocal scanning was controlled by 
Build 143 VistaVision software (ISS Inc.) at 530/43 nm acceptor and 480/40 nm receptor 
wavelengths. Regions of interest were selected with 10 count averages. The lifetime 
determination was obtained by analyzing the first 11–12 modulation frequencies (10–120 
MHz). τα was used to calculate the average D4ER lifetime in different cells/regions. 
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5.2.13 Digital droplet PCR 
To assess β cell death, droplet digital PCR was used to measure serum levels of 
unmethylated insulin DNA using the QX200 Droplet Digital PCR System from Bio-Rad 
Laboratories, as previously described (312). 
5.2.14 Statistical analysis 
Differences between groups were analyzed for statistical significant differences 
using unpaired Student’s t test or one-way analysis of variance with a Tukey-Kramer 
post hoc test. Results are displayed as the means±S.E.M.  GraphPad Prism software 
(GraphPad Software, La Jolla, CA, USA) was employed for data analysis, and a p value 
< 0.05 was taken to indicate the presence of a significant difference between groups.  
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